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ABSTRACT 
Twenty-four apparently unrelated Chinese patients with heterozygous familial 
hypercholesterolaemia (FH) were screened for mutations in the low density 
lipoprotein (LDL) receptor gene by polymerase chain reaction (PCR) followed by 
single strand conformation polymorphism (SSCP) analysis. Mutations of the LDL 
receptor gene were identified in 15 of this group of 24 FH patients. Seventy-six family 
members were also studied for the mutations identified in the respective probands. 
PCR-SSCP analysis protocols were established to screen for sequence variations in 
the promoter and the coding regions of 18 exons of the LDL receptor gene. Twenty 
one sequencing variations, including 13 mutations, 7 polymorphisms and 1 silent 
mutation, were detected as different SSCP patterns. Sequence changes were 
confirmed and identified by direct DNA sequencing. 
The 13 mutations occurred in 15 of the FH patients, seven of them were novel and 6 
have been reported previously. The 7 novel mutations were IlOlF, C308Y, L393R, 
D471N, 1779delC, A606V and C656F. The 6 reported mutations were -44C—T in the 
promoter, 207K, V408M, A606T, P664L and V776M. There was only one single base 
deletion, 1779delC, and the others all single base substitutions. These 13 mutations 
scattered over the LDL receptor gene, from the promoter to exon 16. They consisted 
ofall 5 classes ofLDL receptor mutations affecting various ftmctional domains ofthe 
receptor protein. No association between the plasma total and LDL cholesterol levels 
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and the particular mutation was found presumably due to the small number of FH 
patients. Among the 6 reported mutations, only A606T has been reported in a Chinese 
subject, while the others have been reported in other populations of different ethnic 
origins. However, based on evidence of haplotype analysis, the nature of the base 
changes and the geographical location of Chinese, these mutations were likely to have 
arisen independently. 
P664L was identified in a sister of one FH patient who has the -44C—T mutation. 
One of their brothers was identified as a compound heterozygous FH patient carrying 
both the P664L and the -44C~>T. The P664L was inherited from their father but their 
mother did not carry either mutation, and therefore the -44C—T in the promoter might 
possibly have occurred as a result of germline mutation. One mutation, V776M, 
causing a donor site splicing error was the first of such mutation reported in this gene 
from our study. Each ofthe three mutations, C308Y, L393R and V408M was found in 
two patients. They are possible common mutations in the local FH population. No 
large deletions, insertions and rearrangements were found in this group of FH patients 
by Southern blotting analysis. 
Among the 7 polymorphisms found in this study, one was novel, 1216C/A Mspl in 
exon 9. This Mspl polymorphism was present in 2 FH families but did not co-
segregate with the FH phenotype, despite its absence in 178 normocholesterolaemic 
subjects. The 6 reported polymorphisms found in this group ofFH patients are 81C/T 
SfaNl in exon 2, 1413G/A BsmAl in exon 10, 1617C/T Acil in exon 11, 1773C/T 
Hincll in exon 12, 1959T/C Avall in exon 13 and 2232G/A Mspl in exon 15. These 
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are all common polymorphisms in the coding regions of the LDL receptor gene. The 
allelic frequencies are different from those in Caucasians but similar to Japanese. 
Detection of all the 6 known common polymorphisms indicated our PCR-SSCP 
protocol to be able to detect almost all sequence variations in this gene. 
A silent mutation, 2358C/T Msll in exon 16, was found in one patient, which did not 
change the serine residue at position 765. This mutation was absent in 178 
normocholesterolaemic subjects, it is possible that it is linked to an unknown mutation 
in the LDL receptor gene of this patient. 
The 13 mutations reported here together with the other 12 mutations reported 
previously in Chinese indicates heterogeneity in the LDL receptor gene mutations in 
Chinese FH patients. Out of these 25 mutations, there are one large deletion, 5 small 
deletions and 19 single base substitutions. This pattem of mutations is similar to that 
in other populations. No common mutation due to a founder effect is found But there 
may be regional segregation within China in that common mutations may be present 
in Hong Kong Chinese. 
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Chapter 1: Introduction 
1.1 Cholesterol Metabolism and Atherosclerosis 
In human, lipids are important energy-producing and storage substrates, structural 
components especially of membranes and precursors of many key substances such as 
steroid hormones and bile acids (Stein and Myers, 1994). Table 1-1 shows some 
important lipids in the human body classified according to their chemical structures. 
All human tissues contain lipids of functional and structural roles. Major lipids in 
transporting form in the blood are cholesterol and its esters, triglycerides, fatty acids 
and phospholipids. 
Triglycerides consist of glycerol molecules each of which is esterified with three long-
chain fatty acids, such as stearic and palmitic acids. Triglycerides and fatty acids are 
important energy sources in the body. Fatty acids are also precursors ofprostaglandins 
and cholesterol esters (Stein and Myers, 1994). Phospholipids are similar to 
triglycerides in structure but have one fatty acid residue replaced by a phosphate 
group and a nitrogenous base such as choline. Phospholipids are important 
components of cell membranes and are especially abundant in nerve tissues. 
Cholesterol, also an important component of cell membranes, is a precursor of bile 
acids and steroid hormones. Cholesterol and cholesterol esters are involved in the 
15 
Table 1-1. Classes of important lipids found in human based on their chemical 
structures, (modified from Stein and Myers, 1994) 
Sterol derivatives 














Vitamins A, E and K 
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transformation of macrophages into foam cells which is an important step in the 
process leading to atherosclerosis and subsequently coronary heart diseases (Wissler, 
1991). Studies have been focused on the control and regulation of cholesterol 
metabolism and transport in the pathogenesis of atherosclerosis. 
1.1.1 Cholesterol and Cholesterol Metabolism 
Cholesterol is a tetracyclic perhydrocyclopentanophenanthrene sterol molecule (Fig. 
1-1) with a hydroxyl group at position 3. Free cholesterol is a key component of the 
cell membranes and is the principal form of cholesterol present in most tissues except 
in adrenal cortex, plasma and atheromatous plaques where cholesterol esters 
predominate (Wissler, 1991). Cholesterol ester is formed by attaching a long chain 
fatty acid with the 3-hydroxyl group of cholesterol through an ester bond (Stein and 
Myers, 1994). Formation of cholesterol ester occurs mainly within the vascular 
compartment through the action of the enzyme lecithin cholesterol acyltransferase 
(LCAT). A minor proportion was formed in the liver by the enzyme acyl-cholesterol 
acyltransferase (ACAT). Such esterification enhances the capacity of lipoproteins to 
carry cholesterol. 
There are two sources of cholesterol in the human body, endogenous and exogenous 
(Fig. 1-2). Most tissues have the capability of synthesizing cholesterol from acetate. 
Under normal circumstances the liver is the major site of endogenous cholesterol 
synthesis (Miettinen, 1990). In the biosynthetic pathway of cholesterol the rate 
limiting step is the conversion of P-hydroxyl-P-methylglutaryl coenzyme A (HMG 
17 
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Fig. 1-1 Structure of perhydrocyclopentaophenanthrene (left) and cholesterol. 
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Fig. 1-2 Receptor-mediated metabolism of lipoproteins with cholesterol from 
exogenous and endogenous pathways. Cholesterol derived from diet 
and bile through the exogenous pathway entering into hepatocytes 
could inhibit the hepatic synthesis of cholesterol. Cholesterol carried 
by high density lipoprotein from extrahepatic tissues and low density 
lipoprotein through the endogenous pathway when uptake by the low 
density lipoprotein receptor on the hepatocyte surface could also 
inhibit the hepatic synthesis of cholesterol, and therefore the body pool 
of cholesterol is controlled. 
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CoA) to mevalonate catalyzed by the enzyme HMG CoA reductase, which is subject 
to feedback regulation by the final product, cholesterol (Fig. 1-3). 
Another important source of cholesterol is dietary intake (Miettinen, 1990). 
Absorption of cholesterol occurs in the ileum after solubilization by bile acids. 
Absorbed cholesterol is transported to the liver and taken up by the hepatocytes 
through the low density lipoprotein (LDL) receptor. This LDL receptor mediated 
metabolic pathway is the major route of cholesterol metabolism in plasma (Brown and 
Goldstein, 1986). Free cholesterol entering into the cell can inhibit the HMG CoA 
reductase and thus reduce the hepatic production of endogenous cholesterol. The 
amount of free cholesterol gaining entry into hepatocytes is affected by the amount of 
dietary intake of cholesterol (Fig. 1-2). 
Catabolism of cholesterol takes place exclusively in the liver. The major metabolites 
are the bile acids (Fig. 1-4), and the rate limiting step is the conversion of cholesterol 
to 7-a-hydroxycholesterol catalyzed by the enzyme cholesterol-7-a-hydroxylase 
(Wikvall, 1990). Bile acids in the small intestine are essential for the formation of 
micelles which solubilize free fatty acids, monoglyceride and cholesterol, and hence 
their absorption (Stein and Myers, 1994). Bile acids and cholesterol are excreted in 
the bile, and re-absorbed at the lower third the ileum and returned to the liver via the 
portal vein. This completes the enterohepatic circulation of cholesterol and bile acids. 
Absorption of dietary cholesterol and re-absorption of biliary cholesterol contribute to 
regulate of the rate of hepatic cholesterol synthesis and assist in control of the body 
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Fig. 1-3 Biosynthesis of cholesterol. The rate limiting step is catalyzed by P_ 
hydroxy-P-methylglutaryl coenzyme A (HMG CoA) reductase which 
is subjected to feedback regulation by cholesterol. 
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Fig. 1-4 Catabolism of cholesterol and synthesis ofbile acids. The rate limiting 
step is catalyzed by the enzyme cholesterol-7-a-hydroxylase. 
Cholesterol can also be excreted unchanged in bile, and both the bile 
acids and cholesterol might be re-absorbed at the lower third of ileum 
and the enterohepatic circulation completed. 
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1.1.2 Cholesterol Transport: Apolipoproteins and Lipoproteins 
Lipids are hydrophobic and are transported in the blood stream as complexes with 
proteins called apolipoproteins forming lipoproteins (Alaupovic, 1971). There are four 
major classes of apolipoproteins, apolipoprotein A (apoA), B (apoB), C (apoC) and E 
(apoE) (Alaupovic, 1971; Gotto et al, 1986). They have three main fonctions: to 
solubilize cholesterol esters and triglycerides by interacting with phospholipids; to 
regulate the metabolism of these lipids by acting as co-factors for enzymes such as 
LCAT, lipoprotein lipase (LPL) and hepatic lipase; and to bind to cell surface 
receptors and thus determine the sites of lipid uptake and the degradation rates of the 
lipids and lipoproteins (Mahley et al, 1984). Table 1-2 summarizes some properties 
and functions of apolipoproteins. 
Lipoproteins are traditionally classified by their flotating densities on 
ultracentrifugation as chylomicrons, very low density lipoprotein (VLDL), low 
density lipoprotein (LDL) and high density lipoprotein (HDL) (Havel et al, 1995). 
However, this classification based on physical and chemical properties does not 
convey much information about the functions of lipoproteins (Table 1-2). Table 1-3 
summarizes the composition and some properties of lipoproteins. Lipoproteins are not 
only transport vehicles for lipids in the body, but also undergo continuous changes 
and exchange processes within and between various classes of lipoproteins in the 
blood stream (Eisenberg, 1990). These processes are closely related to the metabolism 
of all lipids, especially cholesterol and triglyceride. 
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Table 1-2. Properties and fiinctions of major apolipoproteins in human, (modified 
from Thompson, 1994) 
Apolipoprotein Lipoprotein Major function Plasma 
association concentration 
(mg/dL) 
A-I HDL, LCAT activator 100-150 
chylomicrons 
A-II HDL Regulation ofhepatic 30-40 
lipase 
A-IV VLDL,HDL, LCAT activator 15 
chylomicrons 
B-lOO VLDL,LDL LDL clearance 90 
B-48 Chylomicrons Triglyceride secretion very low 
C-I VLDL,HDL, LCAT activator .6 
chylomicrons 
C-II VLDL,HDL, Lipoprotein lipase 4 
chylomicrons activator 
C-III VLDL,HDL, Chylomicrons and 12 
chylomicrons VLDL clearance 
E VLDL, HDL Chylomicrons and 3-7 
VLDL clearance 
Abbreviations: HDL: high density lipoprotein 
LCAT: lecithin cholesterol acyl-transferase 
VLDL: very low density lipoprotein 
LDL: low density lipoprotein 
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Table 1-3. Properties and composition of plasma lipoproteins in human, (modified 
from Stein and Myers, 1994) 
Chylomicrons VLDL IDL LDL HDL 
Flotation density <1.006 <1.006 1.006- 1.019- 1.063-
(g/mL) 1.019 1.063 1,21 
Diameter (nm) >70 25-70 22-24 20-23 4-10 
Electrophoretic origin pre_P broad P p a 
mobility 
Composition (% of 
weight) 
Cholesterol 2 5-8 8 13 6 
Cholesterol ester 5 11-14 22 49 13 
Triglyceride 84 44-60 30 11 3 
Phospholipid 7 20-23 25 27 28 
Protein 2 4-11 15 23 50 
Apolipoprotein (%) 
A-I 7 trace - • - 67 
A-II 4 trace - - 22 
B-lOO trace 37 50-70 98 trace 
B-48 22.5 trace trace - -
C 66 50 5-10 trace 5-11 
E - 13 10-20 trace 1-2 
Abbreviations: VLDL: very low density lipoprotein 
IDL: intermediate density lipoprotein 
LDL: low density lipoprotein 
HDL: high density lipoprotein 
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1.1.3 Cholesterol and Atherosclerosis 
There is phenomenal evidence that persistent high cholesterol in the blood circulation 
leads to atherosclerosis. Atherosclerosis is a slow, progressive, degenerative disease of 
blood vessels. The pathological changes found in atherosclerosis including formation 
offoam cells, accumulation oflipids, fibrous tissue and other blood constituents in the 
intima, and the hardening and thickening of the media of the vessel wall (Wissler, 
1991). It is currently the commonest cause of death and disability in most developed 
countries (Thompson, 1994). A growing trend in the occurrence of mortality and 
morbidity related to atherosclerosis can be seen in Hong Kong (Lau et al, 1993). 
The characteristic lesion of atherosclerosis is the fibrous plaque (Fig. 1-5). The 
pathogenesis of plaque formation has not yet been fully elucidated, but the current 
theory is the response-to-injury hypothesis (Ross and Harker, 1976). It proposes that 
endothelial injury to the vascular wall is the first initiation event of the whole process 
(Fig. 1-6). The injury can be resulted from different causes including haemodynamic 
sheer stresses or other mechanical stumuli, toxic or chemical damages such as by 
carbon monoxide from cigarette smoking, viral or immunologic stimuli and increased 
levels of LDL or homocysteine (Cotran and Munro, 1987). Injury causes platelet 
adherence with the production of platelet-derived growth factor (PDGF). PDGF 
attracts monocytes and macrophages to concentrate and surround the injured site. 
Macrophages take up LDL, possibly in the oxidized form, from the bloodstream and 
transform into foam cells forming fatty streaks as the lipid core of the plaque which 
26 
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Fig. 1-5 Diagrammatic representation of an atherosclerotic plaque showing 
outer cap containing collagen and smooth muscle cells, and inner core 
containing foam cells and extracellular cholesterol crystals, (adapted 
from Thompsom, 1994) 
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Fig. 1-6 Schematic representation of possible sequence of events in the 
formation of an atherosclerotic plaque. Different factors including 
hyperlipidaemia might induce endothelial injury which was thought to 
be the first event leading to atherosclerosis. Injury could cause 
gathering of platelets, monocytes and macrophages with secretion of a 
number of growth factors. These factors stimulate macrophages and 
smooth muscle cells to proliferate and take up cholesterol in oxidized 
or other modified forms of low density lipoprotein. These cells would 
transform into foam cells to form the inner core of the atherosclerotic 
plaque, and the proliferated smooth muscle and collagen would form 
the outer core. There are evidences that hypercholesterolaemia can be 
the single factor leading to atherosclerosis. 
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contains mainly cholesterol. Therefore, hyperlipidaemia is an important factor in 
atherosclerosis. Severe hypercholesterolaemia is sufficient alone to cause 
atherosclerosis (Thompson, 1994). However, the precise mechanism by which the 
increased levels of cholesterol induce the atherosclerotic lesion is still unclear. It is 
thought that LDL particles, especially the small and dense LDL, penetrate the arterial 
wall, become oxidized, and am taken up by the macrophages or smooth muscle cells 
for transformation into foam cells (Cotran and Munro, 1987). As a result, fatty streaks 
are formed. HDL has the ability to take up cholesterol from other lipoproteins and 
various tissues including the arterial wall forming HDL-cholesterol, which is then 
carried back to the liver for metabolism. Therefore, HDL has an anti-atherogenic 
effect and is a protective agent for the development of atherosclerosis (Daae et al, 
1993). PDGF together with other growth factors such as interleukins and other 
cytokins stimulate the proliferation of smooth muscle cell which produce excessive 
collagen, elastin and proteoglycans to form the cap of the plaque (Cotran and Munro, 
1987). 
From the results of a number of epidemiological studies (Keys, 1970; Martin et al, 
1986; Assmann and Schulte, 1993; Wilson, 1994), it is known that increase in plasma 
cholesterol levels is one of the major risk factors for the development of 
atherosclerosis and thus coronary heart disease (CHD). In both case-control and 
prospective studies, the cholesterol levels correlate with the prevalence of CHD 
positively (Wilson, 1994). The incidence of CHD is higher in populations such as the 
Finnish with higher mean cholesterol levels than in populations such as Chinese and 
Japanese, both of whom has lower mean cholesterol levels (Chen et al, 1991). About 
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gO% of the plasma cholesterol is found in the LDL fraction, and one LDL molecule 
contains one apoB molecule. The LDL cholesterol and apoB levels are also good 
discriminators for atherosclerosis and CHD (Bhatnagar and Durrington, 1991). 
LDL is taken up by cells through binding of the apoB moiety to the LDL receptor, 
which is the major determinant of the LDL concentration in plasma (Brown and 
Goldstein, 1986). Both environmental factors such as the dietary fat composition and 
genetic factors, e.g. mutations in the LDL receptor and apoB genes, influence LDL 
levels in plasma. These factors affect plasma cholesterol levels and subsequently the 
development of atherosclerosis and CHD (Hegele, 1992; Slyper and Schectman, 
1994). 
1.2 Hyperlipidaemia 
Definition of hyperlipidaemia is based on the results of epidemiological studies on the 
occurrences and risks of developing coronary heart disease. Hyperlipidaemia is 
frequently defined as values greater than the 90th or 95th percentile for the sex- and 
age-adjusted population. Plasma levels of 6.4 mmol/L for cholesterol, and 2.3 mmol/L 
for triglyceride at fasting state are taken as the upper limits of normolipidaemia in 
affluent populations (Schaefer, 1993). 
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1.2.1 Primary and Secondary Hyperlipidaemia 
Primary hyperlipidaemia is genetically determined. Hyperlipidaemia may also be 
secondary to a number of systemic diseases, hormone disorders and drug treatments 
(Thompson, 1994). Table 1-4 shows a classification with causes of hyperlipidaemia. 
Different classifications such as those of Fredrickson (Fredrickson et al, 1967), or as 
modified by the World Health Organization (Beaumont et al, 1970) based on 
hyperlipidaemic phenotypes have been proposed. However, these phenotypic 
classifications of hyperlipidaemia are descriptive, and do not reflect causes which may 
be primary, i.e. genetically determined, or secondary to environmental factors or 
underlying diseases. Furthermore, an individual may change from one class to another 
in response to treatment (Thompson, 1994). Nevertheless, these classifications are 
useful for clinicians to exclude other abnormalities or diseases and help to focus 
attention on the investigations and treatment of hyperlipidaemia. 
Primary hyperlipidaemia may be monogenic or polygenic. Polygenic hyperlipidaemia 
is the result of summated effects of the interactions of many genes and environmental 
factors producing, for instance in cholesterol, a near-Gaussian distribution of plasma 
cholesterol levels in the population (Stein and Myers, 1994). The elevation of plasma 
lipid levels in polygenic hyperlipidaemia is usually moderate, but it affects a large 
proportion of the populations (Houlston and Humphries, 1991). On the other hand, the 







































































































































































































































































































































































































































































































































































































































































































severe. However, these monogenic disorders are rare, and account for only a small 
fraction of primary hyperlipidaemia (Goldstein et al, 1973; Houlston and 
Humphries,1991). Monogenic disorders causing dyslipidaemia ^ e summarized in 
Table 1-5. Some well characterized monogenic disorders are described as below: 
Type IIIHyperlipidaemia Subjects with type III hyperlipidaemia have increased 
plasma cholesterol and triglyceride levels with a characteristic p_migrating very low 
density lipoprotein (VLDL). This p-migrating VLDL which is cholesterol-rich VLDL 
remnant has same electrophoretic migration as LDL to the P position (Mahley and 
Rall, 1995). The primary genetic defect is the presence of a mutant form of 
apolipoprotein E (apoE), apoE-2, which differs from the wildtype apoE-3 by a single 
amino acid, cysteine for arginine at residue 158. ApoE-2 has decreased affinity for the 
LDL receptor, and probably causes a decrease in plasma cholesterol levels (de Knijff 
et al, 1994). There are two forms of type III hyperlipidaemia, recessive and dominant. 
In the recessive form, presence of two apoE-2 mutants together with other genetic, 
hormonal or environmental factors is required are required for the development of 
overt hyperlipidaemia (Mahley and Rall, 1995). These factors include diabetes, 
alcoholism, obesity and hypothyroidism. On the other hand, these factors are not 
required in the dominant form of type III hyperlipidaemia which is caused by the 
presence of a single copy of some mutant alleles of apoE, such as R142C, R145C, 
K146E, an insertion of7 amino acids from residues 121 to 127 (de Knijff et al, 1994), 
or a 10 bp deletion from nucleotide 4037 to 4046 (Feussner et al, 1996). The receptor 
binding ofthese apoE variants is defective. 
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Apo A-I A-I deficiency, A-I/C-III deficiency, Tangier disease 
Apo B Classical abetalipoproteinaemia, familial 
hypobetalipoproteinaemia, familial defective apo B, 
chylomicron retention disease 
Apo C-II C-II deficiency 
Apo E Apo E deficiency, dysfunctional apo E, type III 
hyperlipidaemia 
Enzyme disorders 
LPL LPL deficiency, LPL inhibitor 
Hepatic lipase Hepatic lipase deficiency 
LCAT LCAT deficiency 
Receptor disorders 
LDL receptor Familial hypercholesterolaemia 
Transfer protein disorders 
CETP CETP deficiency 
Abbreviations: Apo: apolipoprotein 
LPL: lipoprotein lipase 
LCAT: lecithin cholesterol acyltransferase 
LDL: low density lipoprotein 
CETP: cholesterol ester transfer protein 
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Familial LCA T Deficiency and Fish Eye Disease Familial lecithin cholesterol 
acyltransferase (LCAT) deficiency and fish eye disease are both characterized by 
comeal opacities. Renal damage and anaemia are found in familial LCAT deficiency 
but not fish eye disease (Glomset et al, 1995). In both diseases there is an inability to 
esterify cholesterol due to LCAT deficiency, and the consequent accumulation of free 
cholesterol in all classes of lipoproteins resulting in lipoproteins with abnormal 
compositions, shapes and concentrations. HDL is usually greatly reduced whereas 
total and LDL cholesterol levels may be normal. Mutations in the LCAT gene are 
responsible for these two diseases. Mutations that affect the a-LCAT activity cause 
fish eye disease, and mutations that affect both a- and P-LCAT activities cause 
familial LCAT deficiency (Glomset et al, 1995). 
Familial Lipoprotein Lipase Deficiency Familial lipoprotein lipase (LPL) 
deficiency is characterized by massive accumulation of chylomicrons and therefore a 
marked increase in triglyceride levels, but the cholesterol levels are normal (Brunzell, 
1995). The LPL enzyme activity is either completely absent or very low, and 
chylomicrons are not hydrolyzed and cleared from the plasma. This is an autosomal 
recessive disorder due to homozygosity or compound heterozygosity in the mutations 
ofthe LPL gene. More than 30 such mutations have been identified (Bmnzell, 1995). 
Familial apoC-IIDeflciency ApoC-II is a co-factor for LPL activity, with 
apoC-II is low or absent apoC-II, LPL activity is reduced, causing 
hypertriglyceridaemia. More than 10 mutations of the apoC-II gene have been 
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reported, producing nil or defective apoC-II. The disorder is inherited in an autosomal 
recessive mode (Brunzell, 1995). 
1.2.2 Mutations leading to Primary Hypercholesterolaemia 
It has been estimated that about two third of the variation in plasma cholesterol in the 
population is determined genetically, whereas the other one third is due to 
environmental factors such as diet (Watakabe, 1981). In monogenic disorders, it is 
important to use the plasma cholesterol level of the 95th percentile of different sex 
and age groups of the local population as the criteria for defining 
hypercholesterolaemia in patients (Schaefer, 1993). 
In the case of primary hypercholesterolaemia, two monogenic defects, familial 
hypercholesterolaemia (FH) and familial defective apolipoprotein B-lOO (FDB), have 
been identified with mutations occurring in the LDL receptor gene and the apoB gene 
respectively (Myant et al, 1991). Both are defects affecting the LDL receptor 
mediated metabolic pathway which is the major route of cholesterol metabolism in the 
plasma (Brown and Goldstein, 1986). A rare autosomal recessive disorder called 
cholesterol ester storage disease (Wolman's disease in its infantile form) also gives 
rise to hypercholesterolaemia. The disease is caused by deficiency of cholesterol ester 
hydrolyase, one of the lysosomal acid lipases. Mutations have been found in the 
cholesterol ester hydrolyase gene, but the properties and effects of these mutations are 
not well understood (Assmann and Seedorf, 1995). 
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Familial Defective Apolipoprotein B-lOO ApoB is the sole apolipoprotein of LDL 
and the binding ligand for the LDL receptor located on cell surfaces. ApoB is one of 
the largest monomeric proteins known, containing 4536 amino acids (Ludwig et al, 
1987). Monoclonal antibody mapping studies have localized the receptor binding 
domain of apoB to the amino acid residues 3000 to 4000. A region from amino acid 
residues 3359 to 3367 is rich in the positively charged amino acids, arginine and 
lysine, as is the apoE LDL receptor binding domain (Knott et al, 1986). However, 
various other studies using antibodies and truncated apoB mutants suggest that other 
regions of the apoB polypeptide are probably required for correct folding of the 
lipoprotein to juxtapose the binding domain to the LDL receptor (Chan and 
Boerwinkle, 1992). 
Studies have been undertaken to identify mutations in apoB that could cause primary 
hypercholesterolaemia. The first such mutation was reported in 1990 (Innerarity et al， 
1990). It is a point mutation at nucleotide 10708 in codon 3500, CGG is changed to 
CAG causing a glutamine at residue 3500 for arginine substitution. This mutation is 
known as familial defective apolipoprotein B-lOO (FDB) because it decreases the 
binding of apoB to the LDL receptor. Recently, a second mutation of apoB has been 
reported to be responsible for primary hypercholesterolaemia. It is a point mutation at 
nucleotide 10800 in codon 3531, the arginine codon CGC is changed to TGC, a 
cysteine codon. This mutation is known as familial ligand-defective apolipoprotein B 
(Pullinger et al, 1995). The codons 3500 and 3531 are outside the putative LDL 
receptor binding domain, i.e. amino acid residues 3359-3367, and the exact 
mechanism by which these mutations affect the LDL receptor binding is not known. It 
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is thought to be due to local conformational changes in and around the receptor 
binding domain (Chan and Boerwinkle, 1992). 
Mutations of apoB, such as FDB, affect the binding of LDL to the LDL receptor and 
are causative for severe primary hypercholesterolaemia. Mutations of the LDL 
receptor also affect its binding to the ligand, apoB, causing familial 
hypercholesterolaemia which is detailed in the following section. 
1.3 Familial Hypercholesterolaemia 
Familial hypercholesterolaemia (FH) was the first genetic disorder known to cause 
myocardial infarction, and it is also a model disease caused by defects in receptor 
molecules (Goldstein et al, 1995). Brown and Goldstein have showed that the LDL 
receptor is a cell surface glycoprotein and is the major determinant of plasma LDL 
level. It regulates plasma cholesterol level by taking up LDL from the blood 
circulation (Brown and Goldstein, 1986). Mutations in the LDL receptor gene are 
responsible for FH. 
1.3.1 Historical Aspects 
Early this century, the association of tendon xanthomata and arterial atheroma was 
frequently described (Goldstein et al, 1995). Family studies in the 1940s and 1950s 
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showed clustering of patients suffering from hypercholesterolaemia, premature 
coronary artery disease and xanthomata. A genetic cause for such condition was 
suggested. After extensive work in Lebanon in the early 1960s, the gene encoding the 
LDL receptor was identified as the cause of hypercholesterolaemia (Khachadurian, 
1964). Since then, the LDL receptor defects and their underlying mutations and 
mechanisms of actions were gradually revealed (Goldstein et al, 1974; Goldstein and 
Brown, 1982; Brown and Goldstein, 1986). 
1.3.2 Clinical Features - Diagnosis and Consequences 
FH is inherited in an autosomal dominant mode and expressed as elevation in plasma 
cholesterol levels leading to skin xanthomata and atherosclerosis (Thompson et al, 
1989). FH heterozygotes have plasma cholesterol levels about twice normal, and 
homozygotes four to eight times. Hypercholesterolaemia may be noted at birth 
(Goldstein et al, 1995), and CHD commonly develops in childhood among 
homozygotes. If untreated, death from myocardial infarction typically occurs before 
the age of 30 years. In contrast, in heterozygotes, CHD only appears in adult life. 
Meanwhile, among hyperlipidaemic survivors of myocardial infarction, 3 to 5 percent 
are FH heterozygotes (Patterson and Slack, 1972). 
Diagnosis of heterozygous FH is mainly based on clinical features and biochemical 
investigations. Elevated total cholesterol and LDL cholesterol levels in plasma, the 
presence oftendon xanthomata, premature coronary artery disease, or similar findings 
in first degree relatives are evidences ofFH (Goldstein et al, 1995). However, several 
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studies have shown that up to 15% of subjects, especially children, are misclassified 
according to these criteria (Koivisto et al, 1992a). Diagnosis can be confirmed by 
measuring the ability of lymphocytes or fibroblasts to bind or internalize LDL. This 
ability reflects the functional aspect of the receptor (Cuthbert et al, 1986). However, 
these cytologic methods for diagnosis are technically tedious and difficult and are not 
reliable for routine use in clinical laboratories. Direct DNA analysis would be useful 
to provide an unequivocal diagnosis (Koivisto et al, 1992a). Moreover, identification 
of specific LDL receptor gene mutations in FH patients allows early and appropriate 
genotype-specific treatment and provides appropriate antenatal care and family studies 
(Feher et al, 1993; Jeenah et al, 1993; Gudnason et al, 1994). 
1.3.3 Population Prevalence 
In the Japanese and most Caucasian populations, the frequency for FH heterozygotes 
is about 1 in 500 ranging from about 1 in 200 to 1 in 1000, and for FH homozygotes, 
the prevalence is about 1 in 1 million (Goldstein et al, 1995; Maruyama et al, 1995). 
FH is probably the most common disease caused by a single gene defect in human 
(Goldstein et al, 1995). In most populations, the LDL receptor gene mutations are 
heterogeneous (Hobbs et al, 1992), however, in a few geographically or culturally 
isolated populations, there are mutations that account for the majority of mutations in 
their FH patients (Table 1-6). Among the South African Afrikaners, two mutations, 
D206E and V408M, comprise about 90% of all the LDL receptor gene mutations 
(Leitersdorf et al, 1989a). Among Lebanese Christians, one mutation, stop 660, 
accounts for almost all oftheir FH patients (Lehrman et al, 1987). These are known as 
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‘founder, mutations. These populations also have a prevalence of FH higher than 1 in 
500 (Table 1-6). Among Lebanese Christians, the heterozygous prevalence is 1 in 
171, French Canadians 1 in 270, South African Afrikaners 1 in 100 and Ashkenazi 
Jews 1 in 67, and the latter probably being the highest prevalence among all 
populations in the world (Goldstein et al, 1995). These high prevalences are 
attributable to the founder effect of a single or a few mutations inherited from the 
same ancestor in their countries of origin. 
1.3.4 Mutations in the Low Density Lipoprotein Receptor Gene 
The LDL receptor gene is located on chromosome 19 between bands pl3.1 and 13.3. 
It consists of 18 exons spanning 45 kb and codes for a 5.3 kb mRNA. Translation of 
2.5 kb of the mRNA produces a mature receptor protein of 839 amino acids (Hobbs et 
al, 1992). The 18 exons code for discrete functional domains of the LDL receptor 
protein (Fig. 1-7) (Goldstein et al, 1995). The signal peptide is encoded by exon 1. 
Exons 2, 3, 5 and 6 each encode for one of the seven repeats of 40 amino acids in the 
ligand binding domain, whereas exon 4 encodes for three such repeats. These 7 
repeats consist of the binding sites for apoB and apoE. Exons 7 to 14 encode a region 
sharing homology with the epidermal growth factor (EGF) gene. In this EGF 
precursor homology domain, there are three cysteine-rich repeats of 40 amino acids, 
A, B and C, encoded by exons 7, 8 and 14 respectively. The repeats A and B are 
separated from C by a spacer region containing five repeats of 40 to 60 amino acids 
encoded by exons 9 to 13. In each of these 5 repeats, there is a conserved motif, Tyr-
Trp-Thr-Asp (YWTD). Exon 15 encodes for the 0-linked sugars domain. Exon 16 
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Table 1-6. Founder mutations of the LDL receptor gene in inbred populations, 
(modified from Hobbs et al, 1992) 
Frequency of Percent (%) of 
Ethnic Geographical FH mutant in FH 
population location heterozygotes Mutant allele heterozygotes 
Ashkenazi Jews SouthAfrica 1/67 AG197 80 
ofLithuanian 
origin Israel not known AG197 33 
Afrikaners SouthAfrica 1/100 D206E 60-70 
V408M 20-25 
D154N 5-10 
Christian Lebanon and 1/170 stop 660 � 1 0 0 
Lebanese Syria 
Franch Quebec, 1/270 5'FR-Inl 60 




Finnish Finland, 1/500 Inl5-Exl8 30-40 
different areas Fs287 34 
G823D 7 
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Fig. 1-7 Structure of the low density lipoprotein receptor protein showing 
different functional domains and relation to the exon orginization of 
the gene. The signal peptide encoded by exon 1 is cleaved from the 
mature protein during synthesis, (adapted from Goldstein et al, 1995) 
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and the 5, half of exon 17 encodes 22 hydrophobic amino acids of the membrane 
spanning domain. The 3, half of exon 17 and the 5, region at the beginning of exon 18 
encode the cytoplasmic domain as the signal sequence for clustering and 
internalization. The LDL receptor is described as a modular protein because its gene 
sequence is homologous to those of other genes such as the C9 complement and EGF 
precursor genes (Sudhof et al, 1985). There is a clear correlation between functional 
domains and discrete exons. This structure and function relationship is important in 
understanding the effect of a particular mutation on the activity of the mature receptor 
protein. 
The transcription of the LDL receptor gene is regulated by sterol mediated repression 
(Sudhof et al, 1987). At the promoter, there are three direct repeats of a 16 base pair 
sequence which is homologous to the consensus DNA sequence, CCGCCC, 
recognized by the positive transcription factor Spl (Dawson et al, 1988). Both repeats 
1 and 3 are Spl binding sites, but repeat 3 is a constitutive positive transcriptional 
element that acts independently of sterol. However, the adjacent repeat 2 contains a 
sterol regulatory element 1 (SRE 1) sequence to which sterol-regulated binding of a 
protein could suppress the activity of the Spl binding in repeat 3 and thus the gene 
transcription (Smith et al, 1990). These three repeats, together with a TATA-like 
sequence, form the LDL receptor gene promoter which is negatively regulated by 
sterols (Sudhof et al, 1987). However, the promoter and these factors can not fully 
account for the physiologic sterol-mediated repression of the LDL receptor gene 
transcription. Other transcription factors such as the SRE binding protein 1 have been 
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shown to upregulate LDL receptor gene transcription (Shachter and Weinberger, 
1994). 
There are more than 200 mutations reported, and they spread over the entire LDL 
receptor gene (Hobbs et al, 1992; Bertolini et al, 1992; Loux et al, 1992; Landsberger 
et al，1992; Koivisto et al, 1992b; Rodningen et al, 1992; Gudnason et al, 1993a; 
Lombardi et al, 1993; Leitersdorf et al, 1993; Top et al, 1993; Leren et al, 1993a; 
Cavanaugh et al, 1994; Leren et al, 1994; Lelli et al, 1994; Jensen et al, 1994; 
Koivisto et al, 1994; Solberg et al, 1994; Nissen et al, 1994; Schluter and Wick, 1994; 
Ekstrom et al, 1995; Pereiva et al, 1995; Leren et al, 1995; Mamyama et al, 1995; 
Peeters et al, 1995; Geisel et al, 1995; Whittall et al, 1995; Lombardi et al, 1995; Sun 
et al, 1995). The mutations are mostly single base changes and small deletions and 
insertions. There are some large deletions and insertions, as well as rearrangements, 
altogether accounting for about 15% of all known mutations. 
LDL receptor mutations can be divided into five classes according to the functional 
defects produced (Fig. 1-8) (Hobbs et al, 1992): 
Class 1 Mutation 
Class 1 mutations are null alleles producing no immunoprecipitable receptor protein 
having a very low percentage of normal LDL binding. These mutations scattered 
throughout the gene, and most of them are nonsense and frameshift mutations, or 
small deletions that create stop codons. Class 1 mutations also include large deletions 
and point mutations which create mRNA splicing errors and thus abnormal sizes of 
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Fig. 1-8 Classification of low density lipoprotein receptor mutations based on 
abnormal function of the mutant protein. These mutations disrupt the 
receptor's synthesis in endoplasmic reticulum, transport to Golgi 
apparatus, binding of apolipoprotein ligand, clustering in coated pits, 
and recycling in endosomes. (adapted from Goldstein et al, 1995) 
46 
mRNA (Hobbs et al, 1992). Mutations involving the promoter sequence leading to 
markedly low level of mRNA are not common presumably due to the relatively small 
size ofthe promoter (Top et al, 1992). 
Class 2 Mutation 
Class 2 mutations, the transport defect alleles, are the most common type, and are 
associated with defective transport of receptor protein from the endoplasmic 
reticulum, which is the site of synthesis, to the Golgi apparatus, which is the site of 
glycosylation and secretion (Hobbs et al, 1992). Transport defects are also common in 
other proteins (Amara et al, 1992), and there may be a cellular mechanism that detects 
protein with incorrect folding or conformation produced from the endoplasmic 
reticulum, rather than the specific mutation or transport involved. Class 2 mutations 
are missense mutations or small deletions that disrupt the correct folding of the 
receptor protein. Two subclasses have been recognized: transport is completely 
blocked in Class 2A and only partially blocked in Class 2B. 
Class 2B accounts for about two-thirds of all Class 2 mutations (Hobbs et al, 1992). 
These mutations are found in exons 2 to 6 which code for the ligand binding domain. 
In this domain, there are 7 repeats each code for one of the 7 ligand binding sites. In 
each repeat, the negatively-charged amino acid residues, Asp-x-Ser-Asp-Glu (DxSDE, 
where x can be any amino acid) for ligand binding and the cysteine residues for 
disulfide linkage are highly conserved (Sudhof et al, 1985). Mutations causing 
substitutions ofthese conserved amino acids would lead to Class 2B mutations. These 
mutations are not evenly distributed among the 7 ligand binding repeats. The repeat 5 
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encoded by the 3'-end of exon 4 contains three times more mutations than any other 
repeats (Gudnason et al, 1993b). This may due to the fact that the 3'-end of the exon 4 
has higher CG content and more CpG hotspots than other exons and therefore more 
missense mutations may occur (Cooper and Krawczak, 1990), or repeat 5 encodes an 
amino acid sequence which plays more crucial roles in the correct folding of the 
receptor protein (Russell et al, 1989). The block in Class 2B is only partial, and some 
proteins could reach the Golgi apparatus and even the cell surface. 
In Class 2A, the block is complete, and no protein can be transported out of the 
endoplasmic reticulum (Hobbs et al, 1992). These mutations are found in the EGF 
precursor homology domain. Half of these mutations are found in the one ofthe three 
cysteine-rich repeats, A, B or C, whereas the other half are found in the spacer region 
between repeat B and C which contains the highly conserved motif, YWTD. It has 
been suggested this region has a compact structure and is easily disrupted by even 
single amino acid changes (Goldstein et al, 1995). 
Class 3 Mutation 
Class 3 mutations, the binding defect alleles, are missense mutations and small 
deletions found at the seven binding repeats of the ligand binding domain, and small 
deletions at the cysteine rich repeats A and B of the EGF precursor homology domain 
(Hobbs et al, 1992). Class 3 mutations are less common than other classes, probably 
because most of them also exhibit the Class 2B transport defect. The defect in the 
ligand binding capacity cannot be studied because of failure to transport the receptor 
protein to the cell surface. Occurrence of class 3 mutations might be under-estimated 
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(Goldstein et al, 1995). Class 3 mutations are point mutations and small deletions of 
the seven binding repeats also occurring at the highly conserved amino acid residues 
as Class 2 mutations. Interestingly, mutation of the isoleucine adjacent to the third 
cysteine of each repeat could also produce such a binding defect mutation (Russell et 
al, 1989). Out ofthe seven binding repeats, only the repeat 5 could bind to both apoE 
and apoB-100, and thus the VLDL and LDL respectively. Therefore, Class 3, or in 
certain cases Class 2B, mutations involving repeat 5 would interfere with the 
clearance of both VLDL and LDL from the plasma. The resultant phenotype is more 
severe than those of mutations with other repeats (Russell et al, 1989). Normal 
binding of LDL but not VLDL also requires the presence of the cysteine-rich repeat 
A in the EGF precursor homology domain. Therefore, deletions in the repeat A would 
reduce LDL binding but not VLDL binding (Goldstein et al, 1995). 
Class 4 Mutation 
Class 4 mutations, the internalization defect alleles, are found in the membrane-
spanning and cytoplasmic domains. The receptor proteins are transported to the cell 
surface and bind the ligand normally, but fail to internalize the bound receptor (Hobbs 
et al, 1992). Class 4 mutations are subdivided into two groups: 4A mutations involve 
the cytoplasmic domain alone and 4B mutations involve both the membrane spanning 
and cytoplasmic domains. Class 4A mutations lead to a receptor protein with delayed 
migration when bound with LDL to the coated pit for internalization, whereas in Class 
4B the receptor proteins are poorly anchored to the cell surface due to deletion ofthe 
membrane spanning domain and are subsequently lost into the surrounding medium. 
The tyrosine residue at position 807 is crucial for internalization. This amino acid 
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residue must be an aromatic amino acid. Tyrosine 807 is part of the tetrameric 
sequence Asn-Pro-Val-Tyr ^SfPVY) in which the proline makes a tight tum and 
exposes the tyrosine or another aromatic amino acid as the signal for directing the 
bound receptor to the coated pit for internalization (Hobbs et al, 1992). This sequence 
is highly conserved in LDL receptors from six different species including Xenopus 
laevis (Chen et al, 1990), and is also present in the cytoplasmic domains of other 
members of the LDL receptor gene family. The latter includes the LDL-related protein 
and VLDL receptor and other cell surface receptors such as the EGF, insulin-like 
growth factor and amyloid precursor protein (Goldstein et al, 1995). 
Class 5 Mutation 
Class 5 mutations, the recycling defective alleles, are quite common. In these 
mutations, the receptor proteins after binding with LDL are internalized normally but 
failed to dissociate in the endosomes. The receptor proteins are then degraded and 
therefore cannot be recycled to the cell surface (Hobbs et al, 1992). These mutations 
are missense mutations and most are found in the EGF precursor homology domain. 
Deletions of the cysteine-rich repeat A and B also produce Class 5 mutations 
suggesting that the repeat A and B play a role in receptor recycling as well. 
Mutations of the LDL receptor gene are not rare, having a prevalence of 1 in 500 in 
most populations (Goldstein et al, 1995), and the resulting increase in plasma levels 
could be effectively treated (Thompson, 1994). Therefore, making correct and early 
diagnosis in suspected heterozygous FH patients is important. However, diagnosis of 
heterozygous FH based only on clinical and biochemical findings is frequently 
50 
equivocal, especially in children (Koivisto et al, 1992a). Genetic diagnosis therefore 
can be useful in making early and unequivocal diagnosis. It also allows antenatal and 
family studies (Reshef et al, 1992). However, because the mutations in the LDL 
receptor gene are heterogeneous and diverse in most populations, and because of the 
large size of the gene, it is difficult to perform genetic diagnosis for FH by detection 
of mutations. What is needed are rapid and reliable methods to detect mutations, 
especially single base changes. Such methods are discussed in the following section. 
1.4 Methods for Detecting Mutations in LDL Receptor Gene 
Methods for detecting mutations are broadly divided into two groups: Southern 
blotting-based and polymerase chain reaction (PCR)-based methods. Nowadays, the 
PCR-based methods are more in use. 
1.4.1 Southern Blotting-Based Methods 
Genomic DNA sample is digested with one or more restriction enzymes and the 
resulting DNA fragments are separated on agarose gel by electrophoresis. The 
separated fragments are transferred by blotting techniques to a nitrocellulose or nylon 
membrane, retaining their electrophoretic positions. Labelled DNA or oligonucleotide 
probes are then hybridized to the separated DNA fragments. Autoradiography of the 
membrane will reveal the hybridized DNA fragments as a pattem ofbands (Southern, 
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1975). Southern blotting is useful for detecting large deletions, insertions and 
rearrangements, and identifying related genes in different species. However, it is 
unreliable to detect small deletions and insertions and unable to detect single base 
substitutions, which account for the majority of gene mutations (Krawczak et al, 
1992). Moreover, Southern blotting could possibly be replaced by long range PCR 
which is capable of producing PCR products up to 20 kb in length (Rodningen and 
Leren, 1996). 
1.4.2 Polymerase Chain Reaction Based Methods 
The polymerase chain reaction (PCR) was first described by KB Mullis and is based 
on the repeated annealing and extension of two oligonucleotide primers that flank a 
specific target DNA segment (Mullis et al, 1986). Because of the amplification effect, 
PCR requires only nanograms of DNA which is much less than that required for 
Southem blotting. Another major advantage of PCR is the availability of automated 
thermocyclers allowing large numbers of samples to be processed with little labor 
within a few hours (Erlich, 1992). Numerous methods utilizing different technical 
approaches are available for the detection of base changes in PCR products (Erlich, 
1992; Cotton, 1993). 
If the mutations have been characterized at the nucleotide sequence level, various 
simple and rapid methods are available to detect the mutation in different samples. If 
the mutation is not known, then it can still be detected by various method. 
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(a) Restriction analysis If the base change creates or destroys the cutting site of 
a restriction enzyme, restriction analysis can be used for detecting the mutation. After 
digestion with the appropriate restriction enzymes and gel electrophoresis, a different 
pattem of bands is obtained with the mutant allele (Rolfs et al, 1992). If the base 
change does not create or destroy a restriction enzyme cutting site, one can introduce 
such a site to the PCR product by using a primer with a mismatch (Rust et al, 1993). If 
the mutation is unknown the PCR products can be digested with a series of restriction 
enzymes until a different pattem is found (Erlich, 1992). However, not all base 
substitutions cause a change at restriction enzyme cutting sites, and this method is not 
able to detect all the mutations. 
(b) Allele-specific oligonucleotide hybridization Short allele-specific 
oligonucleotide (ASO) can be used to distinguish single base changes by 
hybridization with immobilized PCR products. With appropriate stringent 
hybridization and washing conditions, the ASO binds only to the completely 
complementary target sequence, but not to a sequence with even just a single base 
difference, and therefore the normal and mutant alleles can be distinguished (Erlich, 
1992). This method requires the mutation known at the nucleotide sequence. 
(c) Allele-specific amplification The PCR itself can distinguish base substitution 
if the 3'end of one of the primers covers the changed base. The basis ofallele-specific 
amplification is that if a primer is complementary to the normal allele and thus has a 
mismatch with the mutant allele, placing this mismatch at the 3'end of the primer 
would greatly reduce the efficiency of extension by the Taq polymerase, and 
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therefore, the mutant allele will not be amplified. This is called the amplification 
refractory mutation system (ARMS) (Sommer et al, 1992). In an alternative approach, 
tetra-primer PCR puts both the primers complementary to normal and mutant alleles 
in the same PCR tube, and if amplified, different sizes of PCR products will be 
formed for the two alleles which can be revealed by gel electrophoresis as different 
patterns (Ye et al, 1992). 
(d) Length variation If the mutation is related to a difference in the numbers of di-, 
tri- or tetra-nucleotide repeats or a more complicated repeating unit, it can be detected 
as different PCR product sizes by gel electrophoresis (Erlich, 1992). 
(e) Direct DNA sequencing This is the most complete characterization method of a 
PCR product, performed by determining the nucleotide sequence. It can detect both 
known and unknown mutations. With the use of the more specific thermostable DNA 
polymerase (Lee, 1991; Wittwer and Garling, 1991), the double strand PCR product 
can be sequenced directly avoiding the cloning and generation of a single strand 
template. Cyclic DNA sequencing reactions increase the sensitivity and therefore very 
little amount of PCR product as the template is required. Together with the 
availability of automated sequencing instruments with high throughput, direct 
sequencing may become the method of choice in the future (Cotton, 1993). 
( f ) Mismatch cleavage methods When a heteroduplex consists of two single 
strands of two alleles, one base pair is mismatched. This base pair mismatch can be 
detected by chemical or enzymatic cleavage methods such as hydroxylamine/osmium 
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tetroxide and ribonuclease A respectively. Hydroxylamine modifies the mispaired 
cytosine (C) residue by oximation and then the modified C is cleaved by piperidine 
(Cotton 1989). Thus, a mismatch results in cutting of the PCR product, and the 
position of the cleavage site can be determined by gel electrophoresis. This method 
could detect unknown mutations. 
(g) Denaturing gradientgel electrophoresis Denaturing gradient gel 
electrophoresis (DGGE) makes use of the fact that two double strand DNA fragments 
with a single base difference might have different melting temperatures (Tm). 
Therefore, the two DNA fragments can be separated from each other through 
polyacrylamide gel with a gradient of DNA denaturants such as formamide, urea or 
temperature (Fischer and Lerman, 1983). When the fragment reaches the position in 
the gel where the concentration of the denaturant is sufficient to cause DNA melting, 
the migration is retarded. Fragments with lower Tm will migrate slower than 
fragments with higher Tm. DGGE can be used for detecting unknown as well as 
known mutations. 
(h) Single strand conformation polymorphism Similar to DGGE, Single strand 
conformation polymorphism (SSCP) is able to detect both known and unknown 
mutations. SSCP is based on the principle that single strand DNA under non-
denaturing condition will adopt a conformation, presumably by intramolecular 
interactions, which is unique and dependent on the primary nucleotide sequence. This 
conformation might be different even for a single base change. Differences in 
conformation can be detected as mobility shifts in non-denaturing gel electrophoresis 
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(Orita et al, 1988). Different single strands are separated as bands. Theoretically, for 
the heterozygous state, all 4 single strands (sense and antisense strands of each the 
normal and mutant alleles) could have different conformations, and be separated as 4 
bands. Efficiency of SSCP depends very much on the length of the single strand. It is 
optimal for PCR products of 100 to 300 bp in length (Hayashi，1991) with which 
more than 80% of sequence variation would be detected. Conformational changes of 
the single strand DNA depend also on some experimental conditions, which include 
the concentration of detergent, such as glycerol, in the gel and the temperature at 
which the electrophoresis is conducted. Typical conditions are at room temperature or 
4¾, and with or without 10% glycerol in the gel (Hayashi, 1991). In addition, the 
relative acrylamide concentration, degree of crosslinking, double strand denaturation 
and buffer composition may affect the single strand conformation and hence 
efficiency ofSSCP. 
1.4.3 Screening Methods for Unknown Mutations in LDL Receptor Gene 
With the increasing demand for genetic diagnosis in research and clinical services, 
screening methods are required. An ideal screening method should be capable of 
detecting multiple unknown mutations simultaneously; it should be easy and rapid to 
perform with high throughput for a large number of samples. The method should be 
reproducible and able to detect all mutations (Cotton, 1993). 
The mismatch cleavage methods, DGGE and SSCP can all be used for screening PCR 
products for multiple unknown mutations simultaneously. However, the mismatch 
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cleavage methods are technically tedious and involve several biochemical steps and 
reactions. Hazardous chemicals have to be used. This method has been shown to fail 
to detect some mutations (Rossiter and Caskey, 1990). 
DGGE is efficient in detecting single base mutations. It has been employed in the 
screening of mutations in the LDL receptor gene (Lombardi et al, 1995). However, it 
requires specially designed electrophoresis apparatus and long oligonucleotides which 
might be costly, and the melting pattem may be difficult to interpret (Leren et al, 
1993a). 
SSCP of PCR products is also efficient in detecting single base mutations and have 
been shown to be effective for the LDL receptor gene (Hobbs et al, 1992; Loux et al, 
1992; Leren et al，1993a; Leren et al, 1993b; Gudanson 1993a). The procedure of 
SSCP is relatively simple and easier than DGGE. Also SSCP does not require special 
electrophoresis apparatus, but standard apparatus for DNA sequencing. It does not 
require special oligonucleotides as does DGGE. Furthermore, the interpretation ofthe 
SSCP electrophoretic pattem is more straightforward. However, SSCP cannot be able 
to detect all sequence variations, and sometimes it is difficult to reproduce the SSCP 
pattem, especially when the electrophoresis is conducted at room temperature 
(Hayashi, 1992). Nevertheless, because of the great simplicity of SSCP as compared 
to other methods, it was the method of choice for screening unknown mutations in the 
work reported in this thesis. 
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DNA samples from FH patients are also investigated by Southem blotting for the 
following reasons. Firstly, in the LDL receptor gene large gene rearrangements, 
including insertions and deletions are not infrequent (Hobbs et al, 1992), and cannot 
be detected by PCR-SSCP. Secondly, these FH patients are heterozygous and all have 
one normal allele which can be amplified and detected as a normal pattem by PCR-
SSCP even though the other allele may have large gene rearrangements, which can be 
detected by Southem blotting. Therefore, Southem blotting (Horsthemke et al, 1987; 
Sun et al, 1992) was used as a supplementary screening method to PCR-SSCP for 
DNA samples from FH patients. 
1.5 Mutations of the LDL Receptor Gene in Chinese 
Lower plasma cholesterol levels have been reported in Chinese living in mainland 
China, where plasma cholesterol is also related to dietary factors as in other 
populations (Zhou et al, 1995). The plasma cholesterol levels of the Chinese in Hong 
Kong (Fong et al, 1994), Singapore (Loke et al, 1993) and America (Sun and Chen, 
1994) are similar to levels in Westem populations, presumably because dietary intakes 
are similar to the Westem style in the Chinese people of these places. However, the 
genetic variations leading to hypercholesterolaemia in Chinese might be different 
from that in Caucasians. 
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Take apolipoprotein E (apoE) as an example. There is a strong association between 
plasma cholesterol levels and the three common apoE isoforms, E2, E3 and E4, 
encoded by the three alleles, s2, c3 and s4 of the apoE gene. The apoE isoforms could 
explain 10% ofthe variation of plasma cholesterol levels (de Knijff et al, 1994) in that 
E4 is associated with higher plasma cholesterol levels. However, the allelic 
frequencies of the common apoE polymorphisms are different in different populations 
(Hallman et al, 1991; Mak et al, 1996a), the oriental populations including Chinese 
having lower s4 frequencies than Caucasians, and hence lower plasma cholesterol 
levels. 
Polymorphisms of the apoB gene also contribute to the determination of plasma 
cholesterol levels (Humphries, 1988). The Xba\ at codon 2488 and Ins/Del in the 
signal peptide polymorphisms of the apoB gene could explain 6.1 and 4.5 percent of 
the variation of plasma cholesterol levels respectively (Renges et al, 1991), with the 
Del and X+ (presence of the cutting site) alleles associated with higher plasma 
cholesterol levels. These associations also exist in Chinese (Evans et al, 1993; Ye et 
al, 1995), however, the allelic frequencies were different compared to Caucasians. 
There were significantly lower Del and X+ frequencies in Chinese favourable for 
lower plasma cholesterol levels (Saha et al, 1992; Evans et al, 1993). Another point of 
interest is that the prevalence of CHD in Hong Kong Chinese is much lower than 
Caucasians even though plasma cholesterol levels are comparable (Lau et al, 1993). 
This suggests there are other different genetic factors in Chinese responsible for CHD, 
especially as it has been shown that external risk factors associated with CHD are 
probably the same in different populations (Li et al, 1994; Donnan et al, 1994). 
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There is little information on monogenic disorders of hypercholesterolaemia in 
Chinese (Cai et al, 1995). Mutation of the codon 3500 of the apoB gene causing 
familial defective apolipoprotein B-lOO (FDB) has been reported only once in a 
Chinese subject in America (Bersot et al, 1993), but the overall prevalence is 
unknown. The same happens in FH. FH is an important cause of CHD and could 
account for 3 to 5 percent of all CHD patients (Patterson and Slack, 1972). Moreover, 
FH is probably the most common monogenic disorder with preventable consequences 
and effective treatments. Its underlying mutations in the LDL receptor gene have been 
studied in many populations around the world (Goldstein et al, 1995). The prevalences 
of FH in Caucasians and Asians are probably similar (Mamyama et al, 1995). 
Although there is no documented prevalence for Chinese, FH is undoubtedly a 
common disorder leading to atherosclerosis and CHD based on clinical experiences 
(Cai et al, 1995). LDL receptor gene mutations in Chinese are largely unknown. To 
date, only 12 mutations (Table 1-7) have been reported in 2 reports (Hobbs et al, 
1992; Sun et al, 1994). These 12 mutations included one large deletion, four small 
deletions and 7 single base substitutions. Two of them had been reported in other 
populations, while the other 10 were found only in Chinese (Hobbs et al, 1992). With 
a population of 1.2 billion, there must be many more mutations awaiting to be 
discovered. On the other hand, because of the difficulties in the clinical diagnosis of 
FH in heterozygotes (Koivisto et al, 1992a), genetic diagnosis is desirable for early 
appropriate genotype-specific treatment and to allow antenatal and family studies 
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(Reshef et al, 1992). Knowing the mutations should also be useful in elucidating the 
evolutionary and phylogenic relationships between Chinese and other populations. As 
a population, it is important to understand the basic molecular mutations for such a 
common genetic disorder, a pre-requisite both for effective management of the 
patients and counseling of their family members, and also for academic and research 
studies. A detailed study on the mutations of the LDL receptor gene in FH in Chinese 
is required and is reported in this study. 
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Table 1-7. Summary of the 12 mutations reported in the LDL receptor gene in 
Chinese, (modified from Hobbs et al, 1992; Sun et al, 1994) 
Mutation Nucleotide change Exon Predicted effect 
Stop -18 G">A at 12 exon 1 no protein secreted 
632-5 del ACT del ACT at 632-5 exon 4 binding defective 
Stop 207 G ^ T at 682 exon 4 truncated protein 
C249Y G—A at 809 exon 5 slow processing and 
binding defective 
Stop 462 G—A at 1998 exon 10 unstable protein 
L534P T—C at 1664 exon 11 recycling defective 
H562Y C—T at 1747 exon 12 recycling defective 
A606T G ^ A at 1879 exon 13 recycling defective 
Exll-Exl4 8kb deletion exon 11 - 14 no protein 
Fs650 del of C exon 14 no protein 
2015delT (Fs651) del T at 2015 exon 14 truncated protein 
2477delC (Fs850) del C at 2477 exon 17 no protein 
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Chapter 2: Objectives 
2.1 To identify familial hypercholesterolaemia (FH) patients and their family 
members in the local Chinese population based on clinical features and biochemical 
investigations. 
2.2 Establishment of protocols for polymerase chain reaction (PCR)-single strand 
conformation polymorphism (SSCP) analysis of the promoter and the coding regions 
of 18 exons of the low density lipoprotein (LDL) receptor gene to screen for sequence 
variations. 
2.3 Establishment of protocols for direct DNA sequencing of PCR products to 
identify sequence variations detected by SSCP. 
2.4 To search for novel and reported mutations and polymorphisms in this group 
of Chinese FH patients. 
2.5 To search for possible common or founder mutations in the LDL receptor gene 
in local Chinese. 
2.6 To study common polymorphisms and haplotypes in all patients and 
normocholesterolaemic controls. 
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2.7 To compare the mutations and polymorphisms found with those reported for 
the LDL receptor gene in other populations, and to elucidate the possible evolutionary 
relationships between Chinese and other populations. 
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Chapter 3: Materials and Methods 
3.1 Subjects 
3.1.1 Familial Hypercholesterolaemia Patients 
Chinese patients clinically and biochemically diagnosed as familial 
hypercholesterolaemia (FH) heterozygotes attending the Lipid Clinic of the Prince of 
Wales Hospital were recruited into our study. The diagnostic criteria were: (a) fasting 
total and/or LDL plasma cholesterol levels exceeding the 95th percentile of the 
j 
reference interval form the local Chinese population (Table 3-1) (Ho and Chan, 1974; 
Lam et al, 1990; Woo and Lam, 1990; Lau et al, 1993; Fong et al, 1994), and with 
normal fasting plasma triglyceride levels; (b) the presence of tendon xanthomata; 
and/or (c) coronary heart disease, or similar findings in first degree relatives. Family 
members of the probands were invited for screening for the presence of FH. Familial 
defective apolipoprotein B-lOO was excluded in all patients as described (Mamotte 
and van Bockxmeer, 1993; Morash et al 1994). Biochemical tests for baseline plasma 
lipid levels, including plasma total, LDL and HDL cholesterol and triglyceride, and 
I 
for identification of secondary causes of hypercholesterolaemia were performed. 
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Table 3-1. The 95th percentile of plasma total cholesterol and low density lipoprotein 
(LDL) cholesterol in the local population ofHong Kong. 
Cholesterol (mmol/L) 
Male Female 
Age Total LDL Age Total LDL 
20-29 7.0 4.1 20-29 6.8 4.0 
30-39 7.0 4.7 30-39 6.8 4.4 
40-49 7.5 5.0 40-49 7.0 4.8 
50-59 7.5 5.5 50-59 7.5 5.5 
60-69 7.5 5.0 60-69 7.8 5.5 
70-79 7.0 5.0 70-79 7.5 5.5 
80+ 7.0 5.0 80+ 7.5 5.5 
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3.1.2 Normocholesterolaemia Subj ects 
Chinese subjects with plasma cholesterol levels less than the 95 percentile of the 
reference population were recruited from the Medical Out-Patient Clinic as control 
subjects in our study. Baseline lipid tests results, including plasma total, LDL and 






Acil (5,000 U/mL), AvaIl (10,000 U/mL), BamHl (20,000 U/mL), Bbvl (2,000 U/mL), 
BgHl (10,000 U/mL), BsmAl (5,000 U/mL), BsmFl (2,000 U/mL), BrsDl (2,000 
U/mL), EcoRl (20,000 U/mL), Mnll (5,000 U/mL), MsR (5,000 U/mL), Mspl (20,000 
U/mL), Ncol (10,000 U/mL), NlalW (10,000 U/mL), NlalW (10,000 U/mL), Ple\ 
(1,000 U/mL), SfaNl (1,000 U/mL), Pstl (20,000 U/mL) and XbaR (10,000 U/mL) 
accompanied with appropriate 10x buffers and bovine semm albumin (BSA) 
(lOOug/mL) were obtained from New England Biolabs (Beverly, MA, USA). HindRl 
(20,000 U/mL), Hincll (8,000 U/mL), Sstl (10,000 U/mL) and Stul (10,000 U/mL) 
with appropriate 10x buffers were obtained from Pharmacia LKB Biotechnology 
(Uppsala, Sweden). Taq DNA polymerase together with 10x polymerase chain 
reaction (PCR) buffer (500 mmol/L potassium chloride, 200 nunol/L Tris pH8.4) 
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were purchased from GIBCO BRL (Life Technologies, Inc., Geithersburg, MD, 
USA). Moloney murine leukaemia vims reverse transcriptase (M-MLV-RT) 
accompanied with 5x reverse transcription (RT) buffer (250 mmol/L Tris, 375 
mmol/L potassium chloride, 15 mmol/L magnesium chloride, pH8.2) was obtained 
from GIBCO BRL. 
3.2.2 DNA Markers 
HaelW digested pBR322 DNA marker was obtained from Sigma Chemical Company 
(St. Louis, MO, USA), lkb ladder DNA marker was obtained from GIBCO BRL. 
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The double strand direct DNA sequencing kit was obtained from GIBCO BRL. The 
Promega Wizard Minipreps DNA preparation kit was purchased from Promega 
(Promega Corp., Madison, WI, USA). The Rediprime DNA labelling kit was obtained 
from Amersham (Amersham International PLC, Bucks, UK) 
3.2.4 Primers for PCR 
All the sense and anti-sense oligonucleotides were synthesized by the 
phosphoramidite method on a MilliGeny^iosearch Cyclone Plus DNA synthesizer 
from Millipore Corporation (Milford，MA, USA). The oligonucleotides were purified 
68 
f. 
by Oligo-Pak columns supplied by Millipore. Oligo-dT12_i8 for the synthesis of the 
first stand cDNA was purchased from GIBCO BRL 
3.2.5 Chemicals and Reagents 
AcrylamideiZ^w-acrylamide (49:1) 40% solution, agarose, ammonium persulfate, boric 
acid, ethylenediamine-tetraacetate di-sodium salt (EDTA), ethidium bromide, 
formamide，glycerol, Luria-Bertani (LB) broth tablet, polyoxyethylene ether W-1, 
sodium dodecyl sulfate (SDS), sucrose, Tris(hydroxymethyl)aminomethane 
hydrochloride (Tris), Triton X-100, xylene cyanol FF and urea were obtained from 
Sigma. Ammonium acetate, bromophenol blue, cesium chloride, dithiothreitol, 
ethanol (absolute), gaunidinium thiocyanate, hydrochloric acid, isopropanol, 
magnesium chloride, 2-mercaptoethanol, mineral oil, sodium chloride, sodium 
hydroxide, sodium citrate and sodium dihydrogenphosphate were from E. Merck 
(Darmstadt, Germany). The dATP, dCTP, dTTP and dGTP for PCR were purchased 
from Boehringer Mannheim (Mannheim, Germany). Ficoll (type 400) was obtained 
from Pharmacia. N,N,N',N'-tetramethyl ethylenediamine (TEMED) and polyproylene 
tubes of 0.5, 1.5 and 2.0 mL sizes were purchased from Bio-Rad Laboratories 
(Hercules, CA, USA). Ampicillin was obtained from GIBCO BRL. The pLDLR-3 
clone in E coli (ATCC 57004) was obtained from the American Type Culture 
Collection (Rockville, MA, USA). The Kodak XK-1 X-ray film and film developer 
and fixer were obtained from Eastman Kodak Company (Rochester, NY, USA). 
Hybond-N+ positively charged nylon membrane and Rapid-hyb buffer were 
purchased from Amersham. 
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3.2.6 Radioisotopes 
a-32p-dCTP (>6000 U/mmoL, 10 mCi/mL) and y-^^P-ATP (>5000 Ci/mmoL, 10 
mCi/mL) were obtained from Amersham. 
3.2.7 Solutions and Buffers 
-Agarose gel loading buffer (0.25% bromophenol blue, 0.25% xylene cyanol FF and 
15%type 400ficoll) 
-Cesium chloride (5.7 mol/L) 
-Denaturing solution (1.5 mol/L sodium chloride and 0.5 mol/L sodium hydroxide) 
-Diethylpyrocarbonate (DEPC) water (0.1% DEPC, autoclaved) 
-Dithiothreitol (1 mol/L) 
-Ethanol (70% v/v) 
-Ethidium bromide (0.25 ug/mL) 
-Guanidunium thiocyanate (GnSCN) lysis buffer (4 mol/L GnSCN, 100 mmol/L Tris 
pH7.5 and 1% 2-mercaptoethanol) 
-Hydrochloric acid (0.20 mol/L) 
-Neutralization solution (1.5 mol/L sodium chloride, 0.5 mol/L Tris pH7.4 and 0.5 
mmol/L EDTA) 
-Nuclei lysis buffer (10 mmol/L Tris pH8.2, 400 mol/L sodium chloride and 2 
mmol/L EDTA) 
-Phosphate buffered saline (10 mmol/L disodium hydrogen phosphate, 0.9% sodium 




-Polyacrylamide gel loading buffer (80% formamide, 0.1% bromophenol blue and 
0.1% xylene cyanol FF) 
-Polyoxyethylene ether W-1 (10% w/v) 
-Proteinase K (10 mg/mL, in 1% SDS and 2 mmol/L EDTA) 
-Saturated sodium chloride (approx. 6 mol/L) 
-Sodium dodecyl sulfate (SDS, 10% w/v) 
-20x SSC (3 mol/L sodium chloride, 300 mmol/L sodium citrate, pH7.0) 
-Sucrose lysis buffer (320 mmol/L sucrose, 10 mmol/L Tris, 5 mmol/L magnesium 
chloride, 1% Triton-100，pH7.5) 
-lOx TAE buffer (10 mmol/L Tris and 1 mmol/L EDTA, pH7.5) 
-5x TBE buffer (45 mmol/L Tris-borate, 1 mmol/L EDTA, pH8.3) 
-TE buffer (10 mmol/L Tris and 1 mmol/L EDTA, pH7.5) 
3.3 Methods 
3.3.1 Blood Collection 
Blood samples were collected by venipuncture into EDTA tubes from all FH patients, 
their family members and control subjects. Blood samples were stored at -20^C until 
I extraction which was performed within two months. 
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3.3.2 General Biochemistry Tests 
Heparinized plasma was used for the determination of total cholesterol and 
triglyceride on a Dimension AR Chemistry Analyzer (DuPont Diagnostic, 
Wilmington, DE, USA) according to the manufacturer's procedure. High density 
lipoprotein (HDL) cholesterol was determined on Dimension after precipitation with 
phosphotungstic acid reagent from DuPont. Low density lipoprotein (LDL) 
cholesterol was calculated from total cholesterol, triglyceride and HDL cholesterol by 
using the Friedewald formula (Stein and Myers, 1994). Other plasma biochemistry 
tests including renal function tests (sodium, potassium, urea and creatinine), liver 
function tests (total protein, albumin, total bilirubin, alanine transaminase and asparate 
transaminase), calcium, phosphate, y-glutamyltransferase and creatine kinase were 
also determined by using the same analyzer. Plasma glucose was measured on Hitachi 
911 Chemistry Analyzer (Boehringer Mannheim). Thyroid stimulating hormone was 
measured by an two-site chemiluminometric immunoassay on an ACS 180 Analyzer 
from Ciba Coming Diagnostic Corporation (Medfield, MA, USA) 
3.3.3 DNA Extraction 
1 
DNA in a blood sample was extracted according to the salting-out method (Miller et 
! | 
al, 1988). A sample of 2.5 mL EDTA blood was transferred to a 15 mL Elkay 
I polypropylene test tube (Massachusetts Container Corp., Shrewsbury, MA, USA) 
which was then filled with 10 mL of sucrose lysis buffer. The nuclei were sedimented 
by centrifugation using a Sorvall RC28S Centrifuge (DuPont, Newtown, CT, USA) at 
. 
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12,000 g at 4 ¾ for 12 minutes. The supernatant was discarded and the pellet washed 
twice with 10 mL of sucrose lysis buffer followed by centrifugation as above. The 
pellet was then resuspended in 1.5 mL of nuclei lysis buffer and 100 uL 10% SDS and 
50 uL proteinase K were added. The nuclei lysates were digested ovemight at 3TC in 
an incubator under constant shaking (G24 Environmental Incubator Shaker, New 
Brunswick Scientific Co., Edison, NJ, USA). In the next moming, 0.75 mL of 
saturated sodium chloride solution was added and the tube shaken vigorously for 15 
seconds, followed by centrifugation at 12,000 g for 12 minutes. The supernatant 
containing the DNA was transferred to another 15 mL polypropylene tube to which 
two volumes of absolute ethanol were added. The DNA was precipitated out by 
inverting of the tubes and transferred to a 1.5 mL polypropylene tube (Bio_Rad 
Laboratories). It was washed with 70% ethanol. After air drying of DNA, 400 uL of 
TE buffer was added. The DNA samples were stored at 4¾. 
3.3.4 RNA Extraction 
RNA Extraction was performed by the guanidunium thiocyanate (GnSCN) 
ultracentrifugation method (Chomczynski, 1987). Leukocytes from blood collected in 
EDTA were first isolated by Ficoll. One mL of EDTA blood was layered on to 3 mL 
of Ficoll in a 12 mL polyvinyl tube, and centrifuged at 800 g for 20 minutes at room 
temperature. The leukocytes at the interphase were harvested into a 1.5 mL eppendorf 
i 
tube and washed twice with ice-cold phosphate buffered saline. The final cell pellet 
was resuspended in 110 uL of lysis buffer containing 4 mol/L GnSCN, 0.1 mol/L tris 
1 
[ ！ 







solution was layered onto 100 uL of 5.7 mol/L cesium chloride in 0.1 mol/L EDTA 
solution in a 0.2 mL polyvinyl ultracentrifuge tube. Centrifugation was performed at 
80,000 rpm for 2 hours at 20�C on a Beckman TL-100 ultracentrifuge (Beckman 
Instrument Inc., Fullerton, CA, USA). After centrifugation, all the supernatant was 
removed. The RNA pellet was then rinsed with 200 uL of ice-cold 70% ethanol and 
air-dried. The resultant pellet was dissolved in 20 uL of autoclaved water which had 
been treated with diethyl pyrocarbonate (DEPC) and stored at -70^C. 
3.3.5 Polymerase Chain Reaction 
The promoter and the coding regions of the 18 exons of the low density lipoprotein 
(LDL) receptor gene were amplified by polymerase chain reaction (PCR) as described 
(Hobbs et al, 1992). The primers are listed as in Table 3-2. The PCR products' sizes 
ranged from 127 to 355 bp which were appropriate for our subsequent SSCP analysis. 
Exon 4 was amplified with 2 PCRs because of its large size (Hobbs et al, 1992). A total 
of 20 PCRs were carried out for investigation of the LDL receptor gene. 
Each PCR tube contained 50 ng genomic DNA, 100 umol/L of each deoxy-nucleotide 
(dNTP), 15 pmol of each primer, 2.0 mmol/L magnesium chloride and 0.5 U Taq DNA 
polymerase and lx buffer fi:om the manufacturer (GIBCO BRL) in a final volume of25 
uL. The PCR was carried out on a thermal cycler (TC1 Perkin Elmer, Cetus 
j Instruments, Belmont, CA, USA) for an initial denaturation at 95¾ for 5 
74 
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Table 3-2. Primers for amplification ofhuman LDL receptor gene used in the work of 
this thesis, (adapted from Hobbs et al, 1992) 
~~“ “ PCR ~ 
fragment 
5, Primer sequence, 5, to 3, 3, Primer sequence, 5, to 3, size (bp) 
P r 0 m 0 t 0 r GAGTGGGAATCAGAGCTTCACGGGX CCAAGTCATTTACAGCATTTCAATG 1 5 5 
E x o n 1 ACTCCTCCCCCTGCTAGAAACCTCA TTCTGGCGCCTGGAGCAAGCCTTAC 2 3 4 
E x o n 2 CCTTTCTCCTTTTCCTCTCTCTCAG AAAATAAATGCATATCATGCCCAAA 1 9 2 
E x o n 3 TGACAGTTCAATCCTGTCTCTTCTG ATAGCAAAGGCAGGGCCACACTTAC 1 7 6 
E x o n 4 a GTTGGGAGACTTCACACGGTGATGG ACTTAGGCAGTGGAACTCGAAGGCC 3 5 5 
E x o n 4 b CCCCAGCTGTGGGCCTGCGACAACG GGGGGAGCCCAGGGACAGGTGATAG 2 6 5 
E x o n 5 CAACACACTCTGTCCTGTTTTCCAG GGAAAACCAGATGGCCAGCGCTCAC 2 5 2 
E x o n 6 TCCTTCCTCTCTCTGGCTCTCACAG GCAAGCCGCCTGCACCGAGACTCAC 1 7 4 
E x o n 7 AGTCTGCATCCCTGGCCCTGCGCAG AGGGCTCAGTCCACCGGGGAATCAC 1 6 9 
E x o n 8 CCAAGCCTCTTTCTCTCTCTTCCAG CCACCCGCCGCCTTCCCGTGCTCAC 1 7 5 
E x o n 9 TCCATCGACGGGTCCCCTCTGACCC AGCCCTCATCTCACCTGCGGGCCAA 2 7 1 
E x o n 1 0 AGATGAGGGCTCCTGGTGCGATGCC AGCCCTCAGCGTCGTGGATACGCAC 2 9 8 
E x o n 11 CAGCTATTCTCTGTCCTCCCACCAG TGGGACGGCTGTCCTGCGAACATAC 1 6 8 
E x o n 1 2 GCACGTGACCTCTCCTTATCCACTT CACCTAAGTGCTTCGATCTCGTACG 2 0 9 
E x o n 1 3 GTCATCTTCCTTGCTGCCTGTTTAG GTTTCCACAAGGAGGTTTCAAGGTT 2 1 7 
E x o n 1 4 CCTGACTCCGCTTCTTCTGCCCCAG CGCAGAAACAAGGCGTGTGCCACAC 2 0 2 
E x o n 15 GAAGGGCCTGCAGGCACGTGGCACT GTGTGGTGGCGGGCCCAGTCTTTAC 2 4 6 
E x o n 1 6 CCTCACTCTTGCTTCTCTCCTGCAG CGCTGGGGGACCGGCCCGCGCTTA 1 2 7 
E x o n 1 7 TGACAGAGCGTGCCTCTCCCTACAG GCTTTCTAGAGAGGGTCACACTCAC 2 0 7 




minutes, followed by 35 cycles of 95^C for 45 seconds and 68^C for 6 minutes, with a 
fmal extension at 6 f C for 15 minutes. ‘Hot start, method was employed in which the 
Taq DNA polymerase was omitted in the PCR mixture, it was added after the PCR 
tubes were placed in the thermal cycler and heated up to 95¾, then the PCR started. If 
32 
the PCR products were to be used for SSCP analysis, 0.1 uL of a P-dCTP 
(Amersham) was added to each reaction mixture prior to the PCR process. 
A PCR was also set up for study the silent mutation, C—T at nucleotide 2358, found 
in exon 16 in patient L45. This base change created a cutting site for MsR 
(CAYNNMNRIG) and enabled restriction analysis of the PCR product for the 
mutation. However in order to obtain distinct fragments for the mutant, different 
5'primer have been designed for amplification of exon 16 for MsR digestion (Table 3-
3). The primer sequence was 5’ GGCAGAGGAAATGAGAAGAAGCACAG 3’ 
correspond to nucleotide 2329 to 2354 of the cDNA sequence. PCR set up was same 
as above for other exons. 
3.3.6 Agarose Gel Electrophoresis 
Horizontal agarose gel electrophoresis was carried out on a gel electrophoresis 
； 
apparatus from GIBCO BRL. Agarose gel of 1 to 5 % was prepared in lx TAE buffer, 
ethidium bromide (10 mg/mL) was added to give a final concentration of 0.5 ug/mL. 














































































































































































































































































































































































































































































































































































































































































































































































































































































































and samples mixed with loading buffer were loaded into the samples wells ofthe gel. 
Electrophoresis was carried out at 100 mA in lx TAE buffer until the bromophenol 
blue migrated to the desired position on the gel. After electrophoresis, the gel was 
viewed under an ultra-violet (UV) transilluminator at 309 nm (UVP Inc., San Gabriel, 
CA, USA) and a photograph taken with a video camera (Movie Camera HS-CX7, 
Mitsubishi Electric Corp., Japan) using a Kodak Wratten 23A gelatin filter (Sigma) 
and a video copy processor (p66E Video Copy Processor; K65HM Thermal Paper; 
Mitsubishi Electric Corp., Japan). 
3.3.7 Polyacrylamide Gel Electrophoresis 
Vertical polyacrylamide gel electrophoresis was carried out using the Mini-
PROTEAN II apparatus (Bio-Rad Laboratories). Polyacrylamide gel of 6 to 12 % 
(acrylamide:to-acrylamide = 19:1) was prepared in lx TBE buffer using the glass 
plates as provided. DNA marker and samples mixed with loading buffer were loaded 
into the samples wells of the gel. Electrophoresis was carried out at 50 mA in lx TBE 
buffer until the bromophenol blue or xylene cyanol migrated to the desired position on 
the gel. After electrophoresis, the gel was stained in ethidium bromide (0.5 ug/mL) 
solution for 10 minutes. The gel was viewed under an ultra-violet (UV) 
transilluminator at 309 nm (UVP Inc.) and a photograph taken with a video camera 
(Movie Camera HS-CX7) using a Kodak Wratten 23A gelatin filter (Sigma) and a 
! 
1 video copy processor ^)66E Video Copy Processor, Mitsubishi). 
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3.3.8 Single Strand Conformation Polymorphism 
Single strand conformation polymorphism (SSCP) was performed as described 
previously (Gudnason et al, 1993a). Polyacrylamide gels, 6 % (acrylamideiZ?/^-
acrylamide = 49:1) with or without 10% glycerol were prepared in 0.5x TBE buffer 
using a sequencing apparatus (GIBCO BRL). One uL of the ^^P-labelled PCR product 
was mixed with 10 uL of loading dye (95% formamide, 10 mmol/L EDTA, 0.1% 
bromophenol blue and 0.1% xylene cyanol) and denatured at 95¾ for 5 minutes. 
After snap cooling in ice, 6 uL of each reaction mixture was loaded to the gel and 
electrophoresed under 2 conditions: 6 watts (W) at 4^C and 3W at room temperature 
for 16 hours. After electrophoresis, the gel was transferred to a 3MM paper prior to 
drying on a gel dryer (Bio-Rad Laboratories). The dried gel was exposed to a Kodak 
XK-1 X-ray film (Eastman Kodak Co.) at -70�C ovemight, and the film developed. 
Accordingly, each DNA sample from a familial hypercholesterolaemia patient was 
amplified by 20 PCRs following by analysis of each PCR product by SSCP under 4 
different conditions. They were combinations of with or without 10% glycerol in the 
gel and electrophoresis at room temperature (range: 22-25 ^C) or 4¾. The gel used 
was 6% polyacrylamide with acrylamide to to_acrylamide ratio of49 to 1. 
3.3.9 Reverse Transcription - Polymerase Chain Reaction 
Reverse transcriptions (RT) - polymerase chain reaction (PCR) was set up for study 
the V776M mutation found in patient L24. RT was performed using 2 ug of total 
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1 i 
RNA in a mixture containing 0.5 ug of oligo-dT, 50 mmol/L Tris buffer pH8.3, 75 
mmol/L potassium chloride, 10 mmol/L dithiothreitol, 3 mmol/L magnesium 
chloride, 0.5 mmol/L dNTPs and 200 U of Moloney murine leukaemia vims reverse 
transcriptase from GIBCO-BRL in a final volume of 20 uL in diethyl pyrocarbonate 
(DEPC) treated water. The reaction mixture was incubated at 37^C for 1 hour, and the 
reaction terminated by incubation at 90^C for 10 minutes. For the subsequent PCR, 2 
uL of the first stand cDNA was added to a PCR reaction mixture containing 100 
umol/L of each dNTP, 15 pmol of each upstream and downstream primers, 2 mmol/L 
magnesium chloride and 0.5 U Taq DNA polymerase and lx buffer from the 
manufacturer (GIBCO BRL) in a final volume of 25 uL. The upstream primer was 
coded 132, 5，GAGGAAATGAGAAGAAGC 3', corresponding to nucleotides 2333 to 
2350, and the downstream primer was coded 131, 5’ GTTGTGGCAAATGTGGAC 3’， 
corresponding to nucleotides 2506 to 2523 of the cDNA sequence. The PCR was carried 
out on a thermal cycler (TC1 Perkin Elmer) for an initial denaturation at 95¾ for 5 
minutes, followed by 40 cycles at 95�C for 30 seconds, at 58¾ for 30 seconds and at 
72�C for 2 minutes, with a final extension at 72°C for 5 minutes. The ‘hot start，method 
I 
was employed in which the Taq DNA polymerase was omitted in the PCR mixture, it 
was added after the PCR tubes were placed in the thermal cycler and heated up to 95^C, 
then the PCR started. The PCR product was 192 bp in size and was sequenced by a 
t 
















3.3.10 Direct DNA Sequencing 
Samples showing different SSCP patterns were sequenced using a double strand (ds) 
DNA cycle sequencing kit (GIBCO BRL). In the ds DNA cycle sequencing reaction, 
native ds DNA was used as template which was first heat denatured at high 
temperature forming the single strands, primers were annealed to the single strands at 
a lower temperature and extended by the action of Taq polymerase to dideoxy 
termination (Lee, 1991). These three steps of denaturation, annealing and extension 
were repeated for 20-30 times as in PCR. The main advantages of dsDNA cycle 
sequencing method are: (a) the use of ds DNA as template avoids the tedious 
产 
j preparation and purification of single strands, and (b) only very small amount of 
ij template was required for sequencing because of the amplification effect of the cyclic 
reaction (Wittwer and Garling, 1991). 
The primers for PCR were used in the sequencing reactions. They were first labelled 
at the 3'-end with y^^P-dATP (Amersham). One pmol of primer was mixed with 1 uL 
of 5x kinase buffer (300 mmol/L Tris, pH7.8, 50 mmol/L magnesium chloride, 1 
QO 
mmoXfL potassium chloride), 1 uL of y P-dATP (Amersham) and 1 U T4 
polynucleotide kinase in a final volume of 10 uL. The mixture was incubated at 37¾ 
for 30 minutes, and the reaction terminated by heating at 55^C for 10 minutes. The 
end-labeled primer was then stored at -20^C if not for immediate use. 
i' 
I; iV i-. [：• [.; i 
The PCR product was first purified by ammonium acetate and isopropanol 
f 






reaction mixture was first prepared by mixing 5 uL ^^P-labeled primer, 4.5 uL 10x 
Taq sequencing buffer (300 mmol/L Tris pH 7.8, 50 mmol/L magnesium chloride, 
300 mmol/L potassium chloride, 0.5% W-1), 10 ng purified DNA template and 2.5 U 
Taq DNA polymerase. Four sequencing reactions were set up. Termination Mix-A, C, 
G and T, 2 uL of each, was pipetted into separate microfuge tubes and mixed with 8 
uL pre-reaction mixture in each of the 4 sequencing reaction tubes. Thus, the total 
volume in each reaction was 10 uL. One drop of silicone oil was added to each 
sequencing reaction tubes to prevent evaporation. 
The sequencing reaction was carried out on the same thermal cycler using the same 
temperature program as for PCR, the number of cycles being 30. When the reaction 
program was completed, 5 uL stop solution (95% v/v formamide, 10 mmol/L EDTA 
pH8.0, 0.1% w/v bromophenol blue and 0.1% w/v xylene cyanol) was added into each 
sequencing tube to terminate the reaction. The sequencing products were analyzed by 
8% denaturing polyacrylamide gel with 7 mol/L of urea. The polyacrylamide gel was 
prepared in lx TBE buffer using the sequencing apparatus (GIBCO BRL). After a pre-
mn at 70 W for half an hour, 4 uL of each sequencing reaction product, denatured at 
9 5 ^ for 5 minutes, was loaded on to the gel which was then run at 60 W for 3 to 6 
hours. After electrophoresis, the gel was transferred to a 3MM paper and dried on a 
I 
gel dryer (Bio-Rad Laboratories). The dried gel was exposed to a Kodak XK-1 X-ray 
I, 
I' 






Designation of mutations found is according to Beaudet and Tsui's recommendation 
I (Beaudet and Tsui, 1992). 
I 
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3.3.11 Haplotyping ofthe LDL Receptor Gene 
Haplotyping ofthe LDL receptor gene was performed as described (Humphries et al, 
1993; Schluter and Humphries, 1994) for the FH patients and their family members. 
I Four polymorphic sites were studied: SfaNl in e x o n 2, AvaW in e x o n 13, Nco\ in e x o n 
18 and TA repeats in the 3'-untranslated region of exon 18. In addition, as a result of 
the PCR-SSCP analysis, Msp\ in exon 9，BsmAl in exon 10，Aci\ in exon 11, HincW in 
exon 12 and Mspl in exon 15 were also determined for all FH patients and their family 
I members. Therefore, a total of 9 polymorphic sites could be used to define haplotype 
for the mutations found in the LDL receptor gene ofthe 24 FH patients. 
i 
I 




in Table 3-3. For Ncol in exon 18 and TA repeats in the 3'-untranslated region of 
i-
I 丨. 
； exon 18, primers used were as reported (Humphries et al, 1993). For SfaNl in exon 2, 
i: r： 
r 
I exon 9, Acil in exon 11, HincW in exon 12, AvaW in exon 13 and Mspl in exon 15, the 
[： 




f Table 3-2. For BsmAl in exon 10, in order to obtain distinct fragments for the mutant, 
；•' 
i' 1' 
different 5'primer have been designed (Table 3-3). This primer correspond to 
;.. 
nucleotide 1362 to 1386 of the cDNA sequence. The PCRs set up for these 
I polymorphisms were essentially the same as for PCR-SSCP experiments described in 
\ 




I untranslated region of exon 18, the temperature programs were: an initial denaturation 
I 
I at 95¾ for 5 minutes, followed by 30 cycles of 95¾ for 45 seconds，55¾ or 62¾ for 
I i 




Ncol or TA repeats respectively for 45 seconds and 72¾ for 1 minute, with a final 
extension at 72^C for 5 minutes. All polymorphic sites were confirmed by direct 
dsDNA sequencing. 
3.3.12 Restriction Enzyme Digestion 
I If a base change in the DNA sequence, either a mutation or a polymorphism, creates 
I, or destroys a restriction enzyme site, restriction analysis may be used to screen for the 
I base change. Typically, 15 uL ofPCR product with 10 U ofthe restriction enzyme in 
I appropriate buffer was digested ovemight at 37^C. Digestion fragments were a n a l y z e d 
by either agarose or polyacrylamide gel electrophoresis depending on the sizes of the 
i fragments (as above). 







[ The pLDLR-3 clone in E coli (ATCC 57004) (American Type Culture Collection) 
i. 
1 ： ]• 
was reconstituted in 6 mL of LB broth containing 20 ug/mL ampicillin. The culture 
was incubated ovemight at 37¾ with constant shaking. The bacteria were pelleted by 
i' 
r 
centrifugation and the plasmid DNA was extracted using the Promega Wizard 
I 
Minipreps DNA preparation kit (Promega Corp.) according to the manufacturer's 
ES 
' : 
i procedure. The final plasmid DNA was redissolved in 50 uL of TE buffer and stored I >& 
% 




i 84 � y 
I 
The plasmid DNA was digested with appropriate restriction endonucleases to obtain 
the probes for hybridization. Two probes, 5' and 3，，were prepared which can be used 
I for regions covering exons 1 to 11 and exons 11 to 18 respectively. The 5, probe 
[ (i.7kb) was produced by digestion with HinMl and BgRl, and the 3, probe (1.9kb) 
BamHl and Sstl. 700 ng ofthe plasmid DNA (8.9kb) as prepared above was digested 
丨 with 1 U of each two enzymes at 37^C ovemight. The digested fragments were 
separated by 1% agarose gel electrophoresis, and the corresponding bands were cut 
and placed into a preweighed 1.5 mL tube. Water was added to each tube according to 
the weight of the gel, 3 mL of water per gram of gel. The gel was solubilized by 
incubation in boiling water for 10 minutes. The probe solutions were then kept at -
i 
l-i ； 
20^C for storage or at 37^C for immediate use. 
Random priming method with the Rediprime DNA labelling kit (Amersham) was 
used to label the probes. In the 500 uL labelling tube, 10 ng of the probe was added 
i.: 
and mixed. Five uL (50 uCi) of a-^^P-dCTP was then added to the reaction tube. The 
r (• 
I' 
contents were mixed by gentle pipetting up and down and centrifuged briefly. After 
incubation at 37V for 30 minutes, 5 uL of 0.2 mmol/L EDTA was added to stop the 
h'. Q 




Genomic DNA (5-10ug) was digested ovemight at 37�C with 10-14 U of either EcoRl 
[:: 












electrophoresis the xylene cyanol FF reached the bottom edge of the gel. The gel was 
then stained in ethidium bromide (0.25 ug/mL) for 45 minutes. The gel was then 
viewed over the UV light transilluminator at 309 nm (UVP Inc.) to visualise the DNA 
fragment. A photograph ofthe gel was taken with a video camera (Movie Camera HS-
I CX7, Mitsubishi) using a Kodak Wratten 23A gelatin filter (Sigma) and a video copy 
I processor (p66E Video Copy Processor, Mitsubishi). The DNA in the gel was 
depurinated with 0.2 mol/L hydrochloric acid for 10 minutes followed by washing in 
distilled water. The gel was then denatured in lx denaturing solvent for 45 minutes 
followed by washing in distilled water, and neutralization in lx neutralizing solvent 
i 
for two periods of 15 minutes, with a change of the buffer between each period. The 
DNA was blotted on to Hybond-N+ positively charged nylon membrane (Amersham) 
I overnight in 10x SSC buffer (pW.O, 1.5 mmol/L NaCl, 0.15 mol/L sodium citrate). 
After blotting, the membrane was washed in 6x SSC for a few minutes and air-dried 
丨： 
for 30 minutes, then baked at 80°C for 15 minutes. This covalently cross-links the 






i Hybridization of the labelled probe to the fragments on membrane was divided into 
three stages: (a) prehybridization to block the non-specific binding sites of the 
membrane for the probe; (b) hybridization with the labelled probe; and (c) washing 
'(.• 
r^  
I with buffers of increasing stringency to remove residues of the probe bound non-
E. . 
'^ ? �� • 
I specifically to the membrane and so reduce the "background" signal. 
!.:'’： 
f；, 
P (a) Prehybridization: The membrane was placed in the hybridization bottles 
I 





i prehybridized with 10 mL of hybridization buffer (Rapid-hyb buffer, Amersham) at 
i 65^C for 30 minutes in the hybridization oven (Bellco Autoblot Micro Hybridization 
Oven, Bellco Glass, Inc.). 
I (b) Hybridization: The ^^P-lablelled probe was denatured at 96^C for 6 minutes 
I and snap cooled on ice before being added to the bottle for hybridization at 65^C for 2 
hours. 
I： (c) Washing: When hybridization was completed, the membrane was removed from 
the bottle and washed in 30 mL of 2x SSC/0.1% SDS for 10 minutes at room 
r 
i： temperature. This was followed by successive high stringency washes, first with 2x 
L 
I SSC/0.1% SDS for 15minutes at 65°C, second 0.5x SSC/0.1% SDS for 10 minutes 
r. 
I and tris O.lx SSC/0.1% SDS for lOminutes. 
The membrane was then exposed to a Kodak XK-1 X-ray film (Eastman Kodak Co.) 
i. , 
in a Kodak X-Omatic cassette (Eastman Kodak Co.) at -70¾ for 1 to 7 days. 
t 
i ^  h 
1:. I' f 
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Chapter 4: Results 
4.1 Clinical and Biochemical Investigations 
4.1.1 Normal Control Subjects 
i 
A total of 178 normolipidaemic control subjects were recruited. All of them did not 
have been records of cardiac or vascular diseases. Their fasting plasma lipid levels 
i. 
were all below the 95th percentile of the reference interval form the local Chinese 




A total of 24 familial hypercholesterolaemia (FH) patients were identified. Their lipid 
1' 
biochemistry and clinical features are summarized in Table 4-1. Familial defective 
[ apolipoprotein B-lOO was excluded as well as other common secondary causes of 
r 
I. 
hypercholesterolaemia by the plasma biochemistry tests (Table 1-4). All biochemistry 
test results were within the local reference intervals used in the Chemical Pathology 
Laboratory ofthe Prince ofWales Hospital. The plasma total cholesterol levels ranged 
from 7.2 to 13.0 mmol/L, and low density lipoprotein (LDL) cholesterol 5.4 to 11.7 
[• 
mmol/L which were above the 95th percentile ofthe reference interval from the local 























































































































































































































































































































































































































































































































































































































































































































































































































































From 18 patients' families, a total of 76 family members were recruited and entered 
into our study. The recruitment is not exhaustive because some family members 
declined our invitation for participation. No family members of the other 6 patients 
were willing to join our study (Table 4-1). Plasma lipids and other biochemistry tests 
were performed and clinical features of FH examined for making diagnosis in them. 
Once the mutation was identified in the proband, the LDL receptor gene in his/her 












4.2 PCR-SSCP Analysis of LDL Receptor Gene 
i, 
!' • 
i A protocol for PCR-SSCP analysis of the LDL receptor gene was established as 
f； ；：• 
r； 




and polymorphisms. The promoter and coding regions of 18 exons were amplified by 
!• 
}： one each PCR, except exon 4 because of its large size, was amplified by 2 PCRs. A 
total of 20 PCRs were established. All 20 PCR products of each of the 24 patient were 
f (V 
analyzed for SSCP under 4 conditions to search for sequence variations. They were 
combinations of with or without 10% glycerol in the gel and electrophoresis at room 





I Without glycerol in the gel, no differentiation of SSCP patterns could be obtained. 
I :¾. 
I With 10% glycerol, 13 ofthe 20 PCR-SSCP analyses could be detected as having 
i 
I Q . 




Table 4-2. Summary of differentiated SSCP patterns detected or not by different 
conditions for each PCR product of the promotor and coding regions of the 18 exons 
ofthe LDL receptor gene in the 24 Chinese FH patients. 
10% glycerol No glycerol 
PCR room temperature 4"C room temperature 4 C 
p r o m o t o r n o y e s n o n o 
[ exon 1 no no no no 
[ exon 2 no yes no no 
}. exon 3 no no no no 
exon 4a yes no no no 
exon 4b yes yes/no no no 
f exon 5 no no no no 
p exon 6 no no no no 
exon 7 yes yes/no no no 
exon 8 no no no no 
exon 9 yes no no no 
； exon 10 yes yes/no no no 
e x o n 11 y e s n o n o n o 
( exon 12 yes yes/no no no 
exon 13 no yes no no 
S e x o n 1 4 y e s n o n o n o 
exon 15 yes no no no 
f e x o n 1 6 y e s / n o y e s n o n o 
[： exon 17 no no no no 
I 























I 9 at room temperature (Table 4-2). Eight PCR-SSCP analyses were detected with 
different SSCP patterns by electrophoresis at only one temperature, and 5 could be 
j detected at both temperatures, but the resolution was usually better at one temperature 
and weaker at the other. There were 21 differentiated SSCP patterns and they are 
summarized in Table 4-2. 
4.3 Summary of Mutations Identified 
The promoter and the coding regions of 18 exons of the LDL receptor gene in the 24 
Chinese FH patients were screened for unknown mutations by PCR-SSCP analysis 
and direct dsDNA sequencing. Twelve mutations were identified: -44C~>T 
i 
i 
I (promoter), I101F (exon 4), E207K (exon 4), C308Y (exon 7), L393R (exOn 9), 
V408M (exon 9), D471N (exon 10), 1779delC (exon 12), A606T (exon 13), A606V 
j,' 
f (exon 13), C656F (exon 14) and V776M (exon 16) (Table 4-3). Three of them, 
i.' 
!:. 
I C308Y, L393R and V408M, occurred in 2 unrelated patients. Seven out of these 












In the family of patient L25 who had the -44C—T mutation, another mutation, P664L i p 
If 
I which has been previously reported, was identified in one FH member. Another 
§ . 
^ member of this family was found to be a compound heterozygote carrying both 
I 















































































































































































































































































































































































































































































































No conclusion could be drawn on which mutation was associated with higher plasma 
j total and LDL cholesterol levels, although the mutations produced different classes of 
i mutations and defects of the receptor protein which could lead to differences in 
! plasma total and LDL cholesterol levels. If the number of FH patients in each class of 
I mutation was larger, some association may be detected. 
4.4 Novel Mutations 
I (All Figures are shown at the end of Chapter 4, pl06 to pl57) 
I 4.4.1 The first novel mutation was in exon 4，I101F (Fig. 4-la). It was an A—T 
i. 
I. 
substitution at nucleotide 364 in patient L70 (Table 4-3) changing codon 101 for 
i, 
i 
isoleucine (ATC) (the underlined nucleotide represents the site of base change) to 
; phenylalanine (TTC). This mutation was revealed on SSCP with an extra single strand 
band with faster mobility from the PCR product of the 5' half of exon 4 (Fig. 4-lb). 
! The base change destroyed a cutting site for SfaNl (GCATC 5/9)，and restriction 
I analysis was performed for the patient and family members (Fig. 4-lc). On SfaNl 
1 
j digestion the PCR product of the mutant DNA retained its original size of 355 bp, 
while the wildtype DNA would be cut into fragments of 225 and 130 bp. The 
h' 






j 4.4.2 The second novel mutation was in exon 7, C308Y (Fig. 4-2a), and found in 
fl 
1 
1 two unrelated patients L33 and L139 (Table 4-3). This G—A substitution at 
Inucleotide 986 changed codon 308 for cysteine (TGC) to tyrosine (TAC). This -
94 
k 
mutation was revealed on SSCP pattern with two extra single strand bands with 
I slower mobility from the PCR product of exon 7 (Fig. 4-2b). The base change 
destroyed a cutting site for BsrDl (GCAATG 2/0), and restriction analysis was 
performed for the two patients and their family members (Fig. 4-2c). On BrsDl 
digestion the PCR product of the mutant DNA retained its original size of 169 bp, 
i': 1 
f while the wildtype DNA would be cut into fragments of 91 and 78 bp. The mutation 
P f： 




i 4.4.3 The third novel mutation was in exon 9, L393R (Fig. 4-3a), and found in two 
!>： 
!； unrelated FH patients L61 and L66 (Table 4-3). This was a T ^ G substitution at 
丨. 
nucleotide 1241 which changed codon 393 for leucine (CTG) to arginine (CGG). This 
；• mutation was revealed on SSCP with two extra single strand bands with faster 
mobility from the PCR product of exon 9 (Fig. 4-3b). The base change created a 
i 
i 
cutting site for BsmFl (14/10 GGGAC), and restriction analysis was performed for the 
two patients (Fig. 4-3c). On BsmFl digestion ofthe PCR product ofthe mutant DNA 
\ 
produced a fragment of 118 bp, while the wildtype DNA would be cut into fragments 
？: • 
of 87 and 31 bp. The mutation was also found in L175, a FH family member ofL61, 
but family members ofL66 were not available for study. 
4.4.4 The fourth novel mutation was in exon 10, D471N (Fig. 4-4a). This was a 
G—A substitution at nucleotide 1474 changing codon 471 for aspartic acid (GAC) to 
asparagine (AAC) in patient L176 (Table 4-3). This mutation was revealed on SSCP 
i • 
丨 with one extra single strand band with slower mobility from the PCR product of exon 






i restriction enzyme analysis was performed for the patient and family members (Fig. 
f, 
j 4-4c). On Plel digestion of the PCR p r o d u c t of the mutant DNA r e t a i n e d its original 
I size of 298 bp, while the wildtype DNA would be cut into fragments of 156 and 142 
I bp. The mutation co-segregated with the presence of FH phenotype in the family. 
f 4.4.5 The fifth novel mutation was in exon 12，dell779C (Fig. 4-5a). This was a 
single base pair deletion o fC at nucleotide 1779 in codon 572 in patient L39 (Table 4-
[' 3). This mutation produced a frameshift effect and created a stop codon, TGA, 72 
[ codons downstream in exon 14 at codons 643 and 644. Therefore, a truncated and 
inactive protein was expected. From the PCR product of exon 10，this base pair 
i., 
deletion was revealed on SSCP with one extra single strand band with faster mobility 
and one single strand band became migrated faster, and also a heteroduplex double 
strand band (Fig. 4-5b). The bp deletion created a cutting site for NlaW (GGN/NCC), 
and restriction enzyme analysis was performed for the patient (Fig. 4-5c). On NlalY 
digestion ofthe PCR product of mutant DNA produced fragments of 110 and 99 bp, 
while the wildtype DNA retained its original size of209 bp. This was the only small 
[. 
deletion in our study. Unfortunately, no family members were available for study. 
K. 
4.4.6 The sixth novel mutation was in exon 13, A606V (Fig. 4-6a). This was a C ^ T 
at nucleotide 1880 which changed codon 606 for alanine (GCC) to valine (GTC) in 
patient L79 (Table 4-3). This mutation was revealed on SSCP with one extra single 
>? 
Strand band with slower mobility from the PCR product of exon 13 (Fig. 4-5b). The 
r..:. 
; base change destroyed a cutting site for CviJl (RG/CY), but this restriction enzyme is 
_ pi !:, ！ not commercially available and restriction analysis was not performed. However, by 
?• 
ff i? -ij 
I 96 
:i 
PCR-SSCP it was found that the mutation co-segregated with the FH phenotype 
among the family members (Fig. 4-6c). 
4.4.7 The seventh novel mutation was in exon 14, C656F (Fig. 4-7a). It was a G—T 
at nucleotide 2230 which changed codon 656 for cysteine (TGC) to phenylalanine 
(TIC) in patient L73 (Table 4-3). This mutation was revealed on SSCP with one extra 
\ single strand band with slower mobility from the PCR product of exon 14 (Fig. 4-7b). 
;: 
[ The base change destroyed a cutting site for Bbvl (GC/NGC), and the restriction 
enzyme analysis was performed for the patient and family members (Fig. 4-7c). On 
Bbvl digestion ofthe PCR product ofthe mutant DNA produced a fragment of 135 bp, 
[ while the wildtype DNA would be cut into fragments of 79 and 56 bp. The mutation 
co-segregated in the family with the presence of FH phenotype. 
f 










4.5.1 The first mutation that has been previously reported was -44C—T in the 
[::: 
promoter (Fig. 4-8a) in patient L25 (Table 4-3). This mutation was revealed on SSCP 
with one extra single strand band with slightly slower mobility from the PCR product 
r 
of promoter (Fig. 4-8b). The base change destroyed a cutting site for MnFL (CCTC 
7/6), and the restriction enzyme analysis was performed for the patient and family 
|.V'. 
(•:;: 














:i 97 ；-； 
:j 
would be cut into fragments of 72 and 68 bp, while for the mutant DNA the 72 bp 
I fragment was further cut into fragments of 65 and 7 bp. 
4.5.2 The second reported mutation was in exon 4, E207K (Fig. 4-9a). It was a 
[ G—A at nucleotide 682 changing codon 207 for glutamic acid (GAG) to lysine 
I (AAG) in patient L166 (Table 4-3). This mutation was r e v e a l e d on SSCP with one 
I extra single strand band with slightly slower mobility from the PCR product ofthe 3’ 
half of exon 4 (Fig. 4-9b). The base change destroyed a cutting site for MnR (7/6 
I GAGG), and restriction enzyme analysis was performed for the patient (Fig. 4-9c). On 
I Mnll digestion ofthe PCR product ofthe mutant DNA retained its o r i g i n a l size of267 
丨 bp, while the wildtype DNA would be cut into fragments of 192 and 75 bp. The 
mutation was also found in the patient's brother who is suffering from FH. 
4.5.3 The third reported mutation was in exon 9, V408M (Fig. 4-10a). It was a 
}：； G—A at nucleotide 1285 which changed codon 408 for valine (GTG) to methionine 
k 丨. 




with 2 extra single strand bands with faster mobility from the PCR product of exon 9 
[: 
}• (Fig. 4-3b). The base change destroyed a cutting site for NMll (CATGO and 
L 
restriction analysis was performed for the patients and family members (Fig. 4-10b). 
On NlalU digestion the PCR product of mutant DNA would be cut into fragments of 
144 and 127 bp, while the wildtype DNA retained its original size of271 bp. 
I 
(:v' 
i ' : r S I 
I 4.5.4 The fourth reported mutation was in exon 13, A606T (Fig. 4-6a). It occurred at 
f^ i; 





i 1879 which changed codon 606 for alanine (GCC) to threonine (ACC) in patient L75 
5 (Table 4-3). This mutation was revealed on SSCP with one extra single strand band 
i with faster mobility from the PCR product of exon 13 (Fig. 4-6b). The base change 
destroyed a cutting site for CviJl (RG/CY), but this restriction enzyme was not 
S commercially available and r e s t r i c t i o n analysis was not p e r f o r m e d . By PCR-SSCP it 
[ was found that the mutation co-segregated with FH phenotype among the family 




4.5.5 The fifth reported mutation was in exon 14, P664L (Fig. 4-12a). It was a C—T 
I' • 
at nucleotide 2054 that changed codon 664 for proline (CCG) to leucine (CTG) in 
r patient L13 (Table 4-3). This mutation was revealed on SSCP with one extra single 
I' strand band with faster mobility from the PCR product of exon 14 (Fig. 4-7b). The 
： base change created a cutting site for Pstl (CIGCA/G), and the restriction analysis 
i, 
was performed for the patient and family members (Fig. 4-12b). On Pstl digestion the 
[• PCR product ofmutant DNA would be cut into fragments of 107 and 93 bp, while the 
I... 




f ofL25 who has the promoter mutation -44C—T. Later, another family member, L322, 
f.:|. i； 
I was found to be a compound heterozygote carrying both mutations. The pedigree of 
F:. 
this family and results from restriction analyses are shown in Fig. 4-8c. The P664L 
k. 
was inherited from their father, but their mother does not carry either mutation, 
i' ；•；, 
I • • _ 
1^  therefore it is possible that this -44C—T was a germline de novo mutation. 
I . 
^ s i iS 
I 
I 4.5.6 The sixth reported mutation was in exon 16, V776M (Fig. 4-13a). This was a 
j 





i 99 :j 
(ATG) in patient L24 (Table 4-3). This mutation was revealed on SSCP with one 
I extra single strand band with slower mobility from the PCR product of exon 16 (Fig. 
I 4 - 1 3 b ) . The base change did not create or destroy a restriction enzyme cutting site, but 
！ PCR-SSCP showed it co-segregated with the FH phenotype in the family (Fig. 4-13c). 
1 As this nucleotide is also the last base of exon 16, it is possible that this mutation 
I： causes a 5'donor site splicing error. To investigate further, we p e r f o r m e d r e v e r s e 
I transcription (RT) followed by PCR (Fig. 4-13d) using the 5'primer for exon 16 and 
3'primer for exon 17 (Table 3-2). Total RNA extracted from leucocytes in peripheral 
blood from patient L24 was used as template. The PCR product was sequenced and 
only the normal G allele was found (Fig. 4-13e). This suggested that this mutation 











i By PCR-SSCP analysis, from the 24 FH patients, 7 polymorphisms and one silent 
f 
f 
[ mutation were detected. Two of them have not been reported previously (Table 4-4). 
！丨；. 
i' [ 
I i:  
!� 
4.6.1 New Polymorphism 
r 
F 
i^ . f： 
[‘:'： ；•；. ,¾ 
i^  
I 
^ A new polymorphism was found in exon 9 in two unrelated FH patients L148 and 
I 
in 
^ L171. It was a C~>A at nucleotide position 1216, which is the first base of codon 385, 
§ 
j CGG for arginine (Fig. 4-14a). The amino acid is unaltered since AGG is also a codon 






























































































































































































































































































































































































































































































































































































































































































band with faster mobility from the PCR product of exon 9 (Fig. 4-3b). This single 
base change destroyed a Mspl (C/CGG) cutting site and enabled detection of the 
polymorphism by restriction analysis of the PCR product which is 271 bp in size. On 
Msp\ digestion the PCR product ofthe rare allele DNA would be cut into fragments of 
181 and 90 bp, while the wildtype DNA showed bands of 181, 60 and 30 bp (Fig. 4-
14b). All FH family members ofthese two patients carried the rare A allele, but it was 
[ also found in one member of patient L148's family, L144 a male of 27 years of age, 
who was normolipidaemic and is not FH. Since the mutations responsible for the FH 
[ in these two patients were unknown, it was not certain that whether this rare allele was 
[• linked to the mutations. However, the rare A allele was absent in 178 
i normocholesterolaemic subjects. 





I； A new silent mutation was found in exon 16 in patient L45 in whom no mutation was P 
f, 
I found in the LDL receptor gene by PCR-SSCP analysis (Table 4-1). It was a C ^ T at 
I：' 
[ nucleotide 2358 which is the third base of codon 765 (Fig. 4-15a). The amino acid 
was unaltered, since both AGC and AGT encode serine. This mutation was revealed 
i' 
I? on SSCP with one extra single strand band with faster mobility from the PCR product 
K 
of exon 16 (Fig. 4-13b). This base change created a cutting site for MsR 
,¾ 
f3 
I (CAYNNMNRTG) and enabled restriction enzyme digestion analysis of the PCR 
缝 . p 
^ 
I product for the mutation (Table 3-3). After digestion with MsR, the mutant DNA 
8 
I . 
I produced two fragments of 60 and 26 bp, while the wildtype DNA retained the 
J 
original size of 86 bp (Fig. 4-15b). This rare mutation was absent in the other 23 FH 
p ‘ 
i 102 
patients and a group of 178 normocholesterolaemic subjects. Therefore it is possible 
that this silent mutation was linked to the LDL receptor gene mutation that caused FH 
j in this patient. Unfortunately, family members of this patient were not available for 
j study for confirmation. 
4.6.3 Reported Polymorphisms 
丨 Six polymorphisms that had been previously reported were detected in this study 
I： (Table 4-4) by PCR-SSCP analysis and direct dsDNA sequencing ofthe promoter and 
； coding regions ofthe 18 exons. They were the 81C/T SfaNl in exon 2 (Fig. 4-16a, b 
i • i.  
: and c), 1413G/A BsmAl in exon 10 (Fig. 4-17a, b and c)，1617C/T Acil in exon 11 
|, 
(Fig. 4-18a, b and c), 1773C/T HincW in exon 12 (Fig. 4-19a, 5b and 19c), 1959T/C 
Avall in exon 13 (Fig. 4-20a, 6b and 20b) and 2232G/A Msp\ in exon 15 (Fig. 4-21a, 
i b and c). All these six polymorphisms are known to be the common polymorphisms 
I： 
I within the coding regions ofthe exons ofthe LDL receptor gene. 
I： „ 
p 




DNA samples for the 9 FH patients having normal PCR-SSCP results were 
丨 investigated by Southern blotting. The Southern blotting patterns of these nine 
••i 
i:.:. 
； samples were all normal (Fig. 4-22 to 25). This suggested that large deletions, 
丨..； 
I insertions and rearrangements are not present. 
(•-； g ;:: || 
% 
t 
t \ _ «1 ！ 103 
4.8 Haplotypes 
Polymorphisms detected in this study were also included in the haplotype study. A 
total of 9 polymorphic sites were analyzed. The Nco\ polymorphism and the TA 
repeat in exon 18 were the two additional sites to the 7 polymorphisms, SfaNl in exon 
2, Mspl in exon 9, BsmAl in exon 10，Aci\ in exon 11, HincW in exon 12, AvaW in 
exon 13 and Mspl in exon 15, as detailed in Section 4.5. The restriction digestion 
result of Ncol is shown in Fig. 4-26. TA repeats analyzed by polyacrylamide gel 
electrophoresis is shown in Fig. 4-27a, and the repeat numbers of two samples were 
_ 
I confirmed by sequencing as shown in Fig. 4-27b. 
1 y 
i 
I Haplotype results associated with the 13 mutations found in this s t u d y are s h o w n in 
Table 4-5. Using three sites, AvaW in exon 13, Ncol in exon 18 and TA repeat in exon 
I 18, haplotypes could be assigned to 11 mutations in 13 patients, and 5 haplotypes 
i 
m 
I were recognized. The AvaW-, Ncol- and TA=10 was associated with 5 mutations in 6 
patients. The AvaW, Ncol+ and TA=7 was associated with 2 mutations in 3 patients. 
1 The AvaW+, Ncol+ and TA=7 was associated with 2 mutations in 2 patients. The other 
two haplotypes, AvaW-, NcoI+ and TA=8; Avall-, Ncol+ and TA=10, were associated 
with one mutation each. Addition of other polymorphic sites did not further divide 
！ these haplotypes, presumably due to the fact that they are either in linkage 
disequilibrium, such as Hincll in exon 12 with Avall in exon 13, or the rare allelic 








































































































































































































































































































































































































. | • 
i I 
I 
The following conditions were commonly used to obtain results presented from Fig 4-
I 1 to 21 and Fig. 4-26 to 27.unless otherwise stated. In each figure, there are diagrams 
i • 
I for the sequencing, single strand conformation polymorphism (SSCP) and/or 
I restriction analysis results. The experimental conditions for sequencing, SSCP and 
i 
I 
！ restriction analysis are followed. 
i 
i 
I Conditions for Sequencing: 
A double strand DNA cycle sequencing kit (GIBCO-BRL) was used. The primers for 
polymerase chain reaction (PCR) ofthe particular exonA"egion (Table 3-2) were used 
32 • 
in the sequencing reactions. Primers were first end-labelled with y P-dATP using 
I 
reagents included in the sequencing kit. The sequencing reactions were set up 
according to the kit's insert. Sequencing reaction was carried out on the same thermal 
cycler using the same temperature program as for PCR. Finally, sequencing products 
were analyzed by 8% denaturing polyacrylamide gel. Details of the methodology were 
described in Chapter 3, Section 3.3.10. 
Conditions for SSCP: 
32 
SSCP was performed as described previously (Gudnason et al, 1993) for the P-
labelled PCR products. Polyacrylamide gels, 6 % (acrylamide:Z>/5'-acrylamide == 49:1) 
with or without 10% glycerol were prepared using a sequencing apparatus. 
Electrophoresis was performed under 2 conditions: 6 watts (W) at 4^C and 3W at 
106 






room temperature for 16 hours. This resulted in a total of 4 SSCP conditions. Details 
ofthe methodology were described in Chapter 3, Section 3.3.8. 
i 
rnnditions for Restriction Analysis: 
If the base change, either a mutation or a polymorphism, created or destroyed a 
I 
restriction enzyme site, restriction analysis was performed for the patients and/or their 
family members. In a typical experiment, 15 uL of PCR product was mixed with 10 U 
of the restriction enzyme in appropriate buffer and digested ovemight at 37¾. 
Digestion fragments were analyzed by either agarose or polyacrylamide gel 
electrophoresis depending on the sizes of the fragments. The marker used was either 
lkb ladder or Haelll digested pBR322 DNA. Details of the methodology were 
described in Chapter 3, Section 3.3.12. 
LEGEND FOR FIGURES 4-22 to 25 
The following experimental conditions were commonly used to obtain Southem 
blotting results presented from Fig 4-22 to Fig. 4-25 unless otherwise stated. 
Conditions for Southem blotting: 
The pLDLR-3 clone in E coli was used to prepare the 5, and 3, probes by digestion 
with HindmiBgRl and BamHilSstl respectively. The 5, and 3, probes cover exons 1 
to 11 and exons 11 to 18 respectively Probes were than labelled by random priming 











appropriate restriction enzymes and blotted onto Hybond-N+ positively charged nylon 
: membrane after separation ofthe digested fragments by agarose gel electrophoresis. 
Hybridization was then performed with the labelled probe to the membrane. Details of 
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Exon 13，LDL receptor gene, SSCP, 6%(49:1), 10% glycerol, RT 
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Exon 13, LDL receptor gene, SSCP, 6%(49:1), 10% gtycero^ RT 
L131 L135 
L129 L133 
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Exon 14，LDL receptor gene, sequencing, Cysese-TGC^ TJC-Phe 
Normal L73 
A C G T A C G T 
« ^ / ； 
H H ^ ^ ^ ^ ^ i m ^ ^ ^ ^ C GiH657 
W ^ ^ ^ ^ ^ l " * ® * * ^ ^ ^ ^ ® ^ ^ ^ c 
I ^ ^ ^ B ^ ' ^ F ^ H P T Cys/Phe656 
^ s j j | | ^ ^ m ^ ’ c 
4 I H | ^ K ^ \ g Giy6« 
i . ^ % _ " ^ i 5， 
Wbmg^ "'||Hg^ 
^^M|^^.. .,rn^i^|^^|mm^^ ‘ -^ fe^  
Fig. 4-7 Identification ofthe mutation C656F from the PCR product of exon 14 
in patient L73. (a) Confirmation by sequencing, (b) SSCP analysis 
showing C656F and P664L for patients L73 and L13 respectively, (c) 
Bbvl digestion analysis for patient L73 and family members. The 
mutant DNA produced a fragment of 135 bp, while the wildtype DNA 
was cut into fragments of 79 and 56 bp. L97 is the father and L127 the 
brother both carried the mutation. L96, the mother, and L94 and L95, 








:』 丨 （ 3 3 ) 
Exon 14，LDL receptor gen6, SSCP, 6%(49:1), 10%glycerol, RT 
： I ‘ 
I L13 L73 
M^MMwdHkn.' «gM0iMN4HiMMMMMMMMii» 
P^*iiWiW^^^^^ P^P^^ ^^ ^^ ^ •圓 —-“ *^ i . 
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^ ^ ^ ^ ^ ! ^ ^ ^ ! ！ ^ ^|M|g||M^^^M||ta|^^M|^^^^^^^^ fPP^^^^^^i^* ^^^^^^^^^^^^^^^^BIIWH| 
I -
I 
I L13: Pr0664-CCG^CIG-Leu 
I L73: Cys656-TGC^TIC-Phe 
(c) I 
丨 （7¾ 
I Exon 14, LDL receptor gene 
j Cys656-TeC—TIC-Phe, Bbvl digestion 
j 
• i 
I lkb L73 L94 L95 L96 L97 L127 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ m ^ n ^ m i i i i i ^ m i H I I I I I I ^ 
p^^^^^^^H 
^ ^ ^ H 
i ^ ^ ^ ^ ^ ^ ^ ^ B | z l 3 5 b p 
H B H H l l ^ ^ ^ l ^ ^ ^ B :r~79bp 
丨 \ 56 bp 
I 
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Promotor, LDL receptor gene, sequencing, 4C~>T 
Normal L25 
A C G T A C G T 
g ^ - 論 . ， 3 ’ 
m^ « • • ^ E ^ ^ I ^ i / c 
^ ^ ^ ^ ^ i M P ^ ^ ^ • � / G repeat 3 
"mm- " ^ ^ P ^ g ^ i ^ m / T 
^ ^ ^ ^ $ i ^ M t t M k 广 
i >U . ^ ^ ^ mmm. ..^ ..,. -""^^^m^ i 
‘ _ • ^ 
-^^ '• ^ E 暴 一 T 
^^T -mmm- ^^K ^^^ c Ma^^m . J ^ K ： mKm \ c 






I Fig. 4-8 Identification of the mutation -44C—T from the PCR product of 
敏： 
E promotor in patient L25. (a) Confirmation by sequencing, (b) SSCP 
I 
B 
1 analysis, (c) MnR and Pst\ digestion analysis for patient L25 and i 
m 
取； 
I family members for -44C^T and P664L. For -44C->T, the wildtype 
1 
I DNA was cut into fragments of 72 and 68 bp, while for the mutant 
I 
i DNA the 72 bp fragment was further cut into fragments of 65 and 7 bp. 
I 
For P664L, the mutant DNA was cut into fragments of 107 and 95 bp, 
while the wildtype DNA retained the original size of the PCR product 
. 
of 202 bp. L322 was found to be a compound heterozygote carrying 
m 
I both the mutations, 







I (b) (18) 
I Promotor, SSCP, 6%(49:1), 10% glycerol, 4"C 
I L25 
®^ i^®^^^^ ^^^ ^^^ ^^^ d^Oi^^ ^^^®®®®^^^^ ^^^ ^^®®midi®d®®®®®^i^^ ^^^®i(^Mi®i(M®(ji 
single 
strands 




^ ^ ^ ^ ^ ^ ^ • " ^ m n 
L25: promotor,44C">T 
I 
1 _ … ― “ 
(C) (74) 
L25, promotor, -44C^T, Mnli digestion 
L23, Pro664-CCG^CIG-Leu, Pstl digestion 
L322, compound heterozygote of these 2 mutations 
lkb Mnli digestion 
^mm 
m ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 9 "^-155bp 
^^^^^^^^^H z 7 2 b p 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 1 68 bp 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H ^>^65bp 
L13 L23 L25 L321 L322L323 
c _ y ^ 
a^^""^• 






Fig. 4-10 (continued) 
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( a ) 
(28) 
Exon 4b，LDL receptor gene, sequencing, Glu207-GAG^AAG-Lys 
Normal L165 L166 
5， A C G T A C G T A C G T 
, Ser20s Tv 歡 零 、 、 P*# «««t 
：. ^ \ — , — . — — — , 一 I T \ ,|A 舰…〜梦 m^mm'"" 一 . ： ‘ 
I \ n w i w _ .._._ ^ s ^ ^ w w K ( K f 
I Asp206 G \ ^ - … .‘二， -^^ '^¾ 
―： A \ r ^ ^ — 觀 一 ― 贿 一 
J 广 -^*^y---mm .、 •春“龙_^  
i Glu/Lys207 G/A — ^ ‘ ： ~ ^ ^ £ » ： ~ 一 ~ ^ i S ' ~ w ^ 
A * * ^ ^ * * ,..• mmm 
G 产 ， 一 - -y-u-r,iiT*^-— _ _ W i * ^ . 
/ „‘ 一 _ _ _ . .科. — — _ _ • _ _ ； ..,, -!*—«•? ^mrnM � Glu208 G / “ 講 — " * ~ > " > ^ - 一 ~ » ’ ‘ , - - ^ 5 ¾ 
I . / "<ipp^ ^^ **"^  ^toMi^^^(*iiwwiiw* ^**•*"•'*^•^^^^^^. ‘ ^ ' ' " ^ _ ^ ^ ^ s 
I A / 讀 “ ^ . 移 ~ * 一 m m ^ , 
I A / ^ ^ 歡.葱 • 'mmm-'� 
！ Asrt209 A / 一*^ ~-^~ • ««^«爾.： 
I A / , • &-




I Fig. 4-9 Identification of the mutation E207K from the PCR product of 3’ half 
ofexon 4 in patients L165 and L166. (a) Confirmation by sequencing, 
(b) SSCP analysis showing E207K for patient L166 and E200G (YT_ 
27), a known mutation as control, (c) MnR digestion analysis for 
patients L165 and one family member, L166. The mutant DNA 
retained the original size of the PCR product of 267 bp, while the 
wildtype DNA was cut into fragments of 192 and 75 bp. The 75 bp 
band was not seen on the gel. The other lanes were digested PCR 
products from normal subjects. 




I (b) (68) 
I Exon 4b, LDL receptor gene, SSCP, 6%(49:1), 10% glycero^ RT 
I 
i Y T - 2 7 _ _ _ _ _ _ _ _ _ _ _ L 1 6 6 
_ m m m ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ M 
^ H B ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ * ^ ^ ^ ^ ^ ^ ' 
= _ i § _ i I I _ i i i " 
^ ^ ^ ^ M M i i B ^ H ^ ^ ^ ^ ^ K ^ B 
^ H | | B p i ( W ' ^ ^ ' ^ ^ ^ ^ ^ ^ ^ ^ * ^ * ^ 
;j | ^ P ^ ^ _ ‘ % 
I KL:—i :’�•^ 乂 ‘ •‘ 
I 
j YT-27: Asp2oo-GAC^GGC-Gly 
L166: Asp207-GAG^AAG-Lys 
(c) I (60) 
I E x o n 4 b , L D L r e c e p t o r g e n e 




I 1 K b L165 L166 
I 
1 ^ h a t . m]^^^M'^. 
k , ^ ^ M ^ ^ M 
^ i ^ j m l l ^ j i j i ^ ^ j ^ ^ l P i ^ ^ ^ 
^ ^ ^ ^ H ^ ^ ^ ^ P w 3 ^ 2 6 7 b p 
wy^^JM|HH^^^ffiffl^^^.. ^ k'M 餐 ^0»^ 丄 
i B i f l ^ ^ ^ ^ � " i \ 
B H H H I I I B I 1 9 2 b p 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ M M ^ ^ j ^ ^ ^ l ^ ^ ^ ^ 
) I 




E x o n 9 ， L D L r e c e p t o r g e n e , s e q u e n c i n g , V a L w s - G T G ^ A T G - M e t 
L 2 8 N o r m a l 
A C G T A C G T 
^>mmn- mmm . | | | ^ ’ 
4 N H M H i ^ 3 ’ 
I 〜丄一 ‘；等科 M ^ ^ Q 
^ f e flH| / T 
"^W^^^^flR^w j ^ ^ ^ ^ ^ ^ ^ ^ ^ H | M 
… . . ^ m m ^ ^ / G V a L j 0 9 
‘ * ' ' ‘“ ia^Jk.J. 广 '': * '^ '**^ ^g^^#W|ii ^ 
j ' * ^ ‘ - ^ ^ - A l i t t i i # * ^ G / A V a l M e t 4 0 8 
1 '1lfiiiniif^ ^^ ^^ ^ c 
•- � � f ^ -^^^m : \ 
'^m. mmm^ X A 
jJ ‘ ‘ ^^^WP^^RHP^^ . • ^ ^ 
I ^ ^ _ \A Asn407 
j - ’ ， 麵 . 麵 5’ 
: • ， _ . 
Fig. 4-10 Identification of the mutation V408M from the PCR product of exon 9 
in patient L28. SSCP analysis is shown in Fig. 4-3b. (a) Confirmation 
by sequencing, (b) MaIII digestion analysis for patients L86 and 
family members and L28. The mutant DNA was cut into fragments of 
144 and 127 bp, while the wildtype DNA retained the original size of 
the PCR product of271 bp. L87 is the father and L88 the sister ofL86 
and both carried the mutation. The other lanes were digested PCR 
products from normal subjects. 




Exon 9, LDL receptor gene, V a l 4 0 8 - G T G ^ A T G - M e t , N!alll digestion 
i 
L28 L86 L87 L88 丨 mmmm 
m ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ M 一 1 bp 
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i ;. j 
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Exon 13, LDL receptor gene, SSCP, 6%(49:1), 10% glycero^ RT 
L75 L177L178 
«Mil#, ‘ W^ 
_ ‘ 多 ： : 麵 
- * ^ W ® • 1 
smgle 
^ i i ^ ^ ^ ^ M | ^ ^ ^ _ strands 
^^ ^mpi^ di^ ^^ ^^ ^^ p^ "^  
i 繊 ， 









1 …… - -•-
:l 
Fig. 4-11 Identification ofthe mutation A606T from the PCR product of exon 13 
in patient L75. Sequencing analysis is shown in Fig. 4-6b. No 
I restriction analysis for this mutation, (a) SSCP analysis for patient L75 
and her two children. L177 and L178 both carried the mutation. The 
other lanes were PCR products from normal subjects. 
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(a) (34) 
Exon 14’ LDL receptor gerte, sequencing, Pro664-CCG^CIG-Leu 
Li3 Normal 
j A C G T A C G T 
! 3， -
J ‘ ^ ^ 
H^Hr 
G \ 等 * * * 
A '<iHi^  
Glri665 C ***^  丨丨咖 一. M^^ 
G € M ' ^ ^ 
I cn — • � � ‘ 
Pro/Leu664 C _ _ * * * * 
c^ % H 
A1^ G / 一 . . W^ 
5， • . • . . ； ,.Z?^ ' .^««> 
• � m m 
Fig. 4-12 Identification of the mutation P664L from the PCR product of exon 14 
in patients L13. SSCP result is shown in Fig. 4-7b. (a) Confirmation by 
丨 sequencing, (b) Pst\ digestion analysis for patients L13 and family 
.1 
:i 
;j members. The mutant DNA was cut into fragments of 107 and 95 bp, 
j 
^ while the wildtype DNA retained the original size of the PCR product 
of 202 bp. L6, L23 and L26 are the sisters, L76 nephew of L13 all 
carried the mutation. L25 is another sister who does not carry this 
mutation, but the -44C—T mutation (see also Fig. 4-8c for more 
informations). 




Exon 14，LDL receptor gene 
Pro664-CCG^CIG-Leu, Pstl digestion 
lKbL6 L13 L23 L25 L26 L76 
^ H 
H ^ ^ ^ P | m P P P ^ ^ ^ ^ 2 0 2 bp 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H ——bp 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 1 ^ ^ 9 5 bp 
丨… 一 … … … . . “ — 
Fig. 4-10 (continued) 
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� I (12) 
I Exon 1 6 , LDL receptor gene, sequencing, V a l 7 7 6 -GTG^ATG-Met 
L24 Normal Normal 
I 3, A C G T A C G T A C G T 
a \ ^ ^^t|^ ^^3^ K^^^^^^ K^^L 
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^m 
Valm G/A— ^ | H i | ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ B CT ^ n ^ ^ ^ H 
ne775 l ^ H | ^ H ^ H | ^ p ^ ^ ^ H c^ I ^ ^ ^ H ^ E H H 
人 � r � 4 1 C V W R 
Lai773 C I 
5' 
Fig. 4-13 Identification of the mutation V776M from the PCR product of exon 
16 in patients L24. (a) Confirmation by sequencing, (b) SSCP analysis, 
(c) SSCP analysis showing V776M for patient L24 and family 
members, and 2358C/T MsH silent mutation for patient L45. L277 and 
L279 are children of L24 carried the mutation, and L278 a normal 
child, (d) reverse transcription (RT)-PCR result of cDNA from patient 
L24 showing one single band of RT-PCR product, (e) Sequencing 
result of the RT-PCR product from patient L24 showing only the 
normal G allele was present. 
(to be continued) 
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( b ) 
(35) 
Exon 16，SSCP, 6%(49:1), 10% glycerol, 4X 
L24 
S - . • • • • , •‘ • » • •, -• � .« - » •_ • 
• '. • ; . . ‘ 
. : • • • • .',；.,, . » :•(" , • V 
‘ ‘ ‘ ‘ “ r ‘ . \ • I 
^ | , : ‘ vj \ . ‘ single 
譯 . . . . * … ： 染 , ‘ • � ： -.^  ’…為 strands 
. , . , r r ‘ — ，、 - ^ ‘...••• : .,..' . ;v : : . . . . , - , . - , . , • 
! 
L24: Val776-GTG^ATG-Met, splice error 
(c) 
(77) 
Exon 16, SSCP, 6%(49:1), 10% gIycero^ 4^C 
L277 L279 
L45 L24 L278 
^ ^ ^ 
醫-.^^^n^^^^^^ 
s ing le 
s trands 
^ ^ g M y i 
^nm^BRi^^^^^^ 
L24, L277, L279: Va l776 -GTG^ATG-Met , splice error 
Fig. 4-13 (to be continued) 133 
(d) 
(70) 
LDL receptor gene 
RT-PCR ofcDNA from L24 
with Val776-GTG^ATG-Met 
1 2 3 4 
H^ 1636bp 1018bp 
^ ^ ^ ^ ^ ^ 9 ~ ~ ~ 2 2 0 b p 
^ ^ B H [ ^ H ^ \ 201 bp 
Lanes: 1 - genomic DNA onty 
2 - mixture of genomic DNA and cDNA 
3 - cDNA onty 
4 - lkb marker 
(e) ( 5 1 ) 
L D L r e c e p t o r g e n e , s e q u e n c i n g o f c D N A f r o m L 2 4 w i t h V a l 7 7 6 - G T G - > A T G - M e t . 
I L 2 4 
i A C G T 
^^ |^jjjUjjjjj|p^ ?^ !"""^ ._" r ‘ "'“‘ "^^^^^^^^^^^^^^^^^L 
' ^ m ^^B 5’ 
- ^ : ^ ^ ^ ^ B b v - J ^ ^ K . / A I l e 7 7 5 
* ^ S s J B ^ j 
4 f N i H | | | | | | | | | | ^ ^ ^ ^ ^ ^ G e x o n 1 6 V a l 7 7 6 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H | T e x o n 1 7 
3|f^ ^B ？ -
. . ^ ^ ^ ^ m i ^ ^ m m ^ ^ ^ ^ ^ \ C L e u 7 7 8 
• ^ ^ ^ ^ ^ ^ ^ g f \ T 
' ^ ^ ^ ^ ^ ^ ._J^^^^H \ Q 
i y u y | ^ B r 3, 
I ^ ^ i mm 




Exon 9, LDL receptor gene, sequencing, Argsss-CZAGG, Mspl polymorphism 
L148 Normal 
A C G T A C G T 
3’ � — « ^ ^ ^ 
'^'^ ®^®^^^^ "^WWBWBP^ 
c .^ ilHlliH^  ^ ^ ^ n n ^ ^ ******^  ^^ ^^ ^^ ^^ ^^ ^^ ^ ^mgj^ ^^ HRiliP^  
A 0HtKtl^^^^^ j^^^pHP^' 
HiS386 C ^ ^ ^ ^ , 
G 
G 4rnmm • mmm 
Arg385 C/A — • • ^-"^m^ fUllP" 
^^  .^^KBW(fc^- m^^^^^ npiB^. 
A __^ ,^ ^mmm- ^ f H | L ^ 
Asn384 A^^ gMg|^ ^^^^mmm^ 
_ _ W K m _ J P r 
^ j ^ j U g | ^ ^ w ^ ^ . . , ^ M | ^ | U U ^ M ^ ^ H P P i ^ ' 




Fig. 4-14 Identification of the 1216C/A polymorphism from the PCR product of 
exon 9 in patient L148. SSCP analysis is shown in Fig. 4-3b. (a) 
Confirmation by sequencing, (b) Mspl digestion analysis for patient 
L148 and family members. The rare allele DNA was cut into fragments 
of 181 and 90 bp, while the wildtype DNA 181, 60 and 30 bp. L144, a 
normolipidaemic member who is a male of 27 years of age, also 
possessed the rare allele A. The half filled symbol indicates carrier of 
the rare allele. The polymorphism did not co-segregate with the FH in 
the family indicated by the low density lipoprotein cholesterol (LDLC) 
levels (mmol/L). The 95th percentile of LDLC of the local population 
which is 5.5 mmol/L was used as one of the diagnostic criteria for FH. 
(to be continued) 
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(b) (55) 
Exon 9, LDL receptor gene, Arg385-CZAGG, Mspl digestion 
L242 L149 L148 L146 L147 L142 L145 L143 L144 
^ H 
^ ^ ^ ^ ^ B ， b P 
^ m ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ | 一 9 0 bp 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H _ 6 0 bp 
I l.�—1 
1 • W : .L_J 
f ^ T 1 r 1 '1 ‘ 1 .1 
^ _ . . . . ^ _ ,—J-- - . W 人 ！ ‘-一 ： ‘ • ~ H | 
.1 I ^ : ' I L�Gl 
I U ) L - C “ 6 9 ^7 .V4 7 7 14 ” 2.'> 4 2 
1 (mmoLn) 丨 
1 — — — . . . _ ^ _ _ _ 
Fig. 4-10 (continued) 
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( a ) 丨 （13) 
i Exon 16，LDL receptor gene, sequencing, Ser765-AGCT 
1 
i Normal L45 Normal 
3. A C G T A C G T A C G T 
Gv ^ m g n m i i ^ ^ ^ i i i i m i 
Arg767 \ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ | ^ ^ ^ ^ ^ P 
^ ^ ^ ^ ^ ^ ^ H | ^ ^ K 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ • n ^ ^ ^ ^ V 
^ - S ^ ^ ^ ^ O ^ B 
SeT765 ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H ^ ^ ^ ^ ^ | ^ H | p 
m H ^ ^ ^ ^ ^ m ^ ^ ^ ^ ^ 
A . ^ ^ H H ^ ^ ^ ^ ^ | ^ ^ ^ ^ ^ | B 
Pr0763 ^ ^ ^ ^ ^ ^ ^ ^ ^ | ^ | H ^ ^ | ^ ^ | p 
' ^ ^ ^ ^ ^ ^ ^ ^ ^ • ^ • H 
^KmKm^^^KKKK^^^^^^^^^^^^^^^^^ 
Fig. 4-15 Identification of the 2358C/T MsR silent mutation from the PCR 
product of exon 16 in patient L45. SSCP analysis is shown in Fig. 4-
13c. (a) Confirmation by sequencing, (b) MsR digestion analysis for 
patient L45. The mutant DNA produced two fragments of 60 and 26 
bp, while the wildtype DNA retained the original size of the PCR 
product of 86 bp. The other lanes were digested PCR products from 
normal subjects. 




Exon 16, L D L receptor gene 
Ser765-AGC^AGT- Ser, MsK polymorphism 
他 L 4 5 
H ^ B 
[ ^ ^ ^ ^ ^ ^ ^ ^ ^ 9 — 86 bp 






Fig. 4-15 (continued) 
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( a ) (7) 
Exon 2, LDL receptor gene, sequencing, CyS6-TGOT, SfaNl polymorphism 
L119 Normal 
5’ A C G T A C G T 
-^''^m^- 'tMroi^ i. • 




Cys6 T m m 幾 
G , ^ : 
CAT- " * • ^ 
1 i-
Glu7 G * * - ^ * » 
A ^ . 
• ^ lflNWlH^._ 
A Z , . . .. _ 
imUpt :4pHMi ,.. 
3' .- 事 ^ 
i, <rf.4««^  W^M'^ 
^�- 4lpw*-^
^ | y g | ^ ^ . 
'V^i#*<MHIK^  i^ W^^ ^^  _. 
«M» « » 
. 
Fig. 4-16 Identification of the 81C/T SfaNl polymorphism from the PCR product 
ofexon 2. (a) Confirmation by sequencing ofDNA sample from L119 
who is heterozygous for the polymorphism, (b) SSCP analysis ofDNA 
sample from L75, a heterozygote. (c) SfaNl digestion analysis. The rare 
allele DNA produced fragments of 100 and 92 bp, while the wildtype 
DNA produced fragments of 100, 58 and 34 bp. The 34 bp band was 
not seen on the gel. 




Exon 2, SSCP, 6%(49:1), 10% glycerol, 4°C 
L75 
. - • , ；.- ,• V . 
, ti • 看 
^ ^ 1 ^ ^ ^ ’ ^ ^ ^ ‘ single 
m i P H < ^ ^ m > ^ : strands 
iiiiiiiiitol^ ^^ ^^ ': ‘ ^ ^^^^r 
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^HBBHIPPW 'i'JiWi^>-;“ 
•••'58Tx'*wl5s^.-:.'^.-y‘ ,:-r<:iy^'- .�.. • 
L75: Cys6-TGGI SfaNl polymorphism 
(c) 
丨（63) 
I Exon 2, LDL receptor gene, Cys^ -TGC/T, SfaNl polymorphism 
I 
！ 
I pBR322 C/C CfT crr 
^^m 
H B B J M P P W i l M B 100 bp 
m n K j i m i f ^ i f i i i — 9 2 bp 
E ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
^B^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ |^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ B 
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Exon 10’ LDL receptor gene, Argasn-AGG/A. BsmAl polymorphism 
I 
I L19(G/G) L176(G/A) L187(A/A) 
A C G T A C G T A C G T 
3 , ^ ^ - m m m * w r ^ 
m ^ ^ H ^^ sJB^MiB^^ _>^ <i^ iMBfc ^ ^ ^ * ^ 
C \ ^ ^ ^ ^ ^ ^ m 
. A \ S l f t L ^ 9 ^ ^ ^ ^ ¾ ! 
" ' " i - j n s ^ 
； ‘ \ J 3 P ^ P . J g ^ ^ 
u z 2!2THHr ^^^<^jil^^^|^^^^ilMHimHib ^^^ 





Fig. 4-17 Identification of the 1413G/A BsmAl polymorphism from the PCR 
product ofexon 10. (a) Confirmation by sequencing, (b) SSCP analysis 
(see also Fig. 4-4b). (c) BsmAl digestion analysis. The rare allele DNA 
produced fragments of 114, 92 and 16 bp, while the wildtype DNA 
produced fragments of 114 and 108 bp. 
(to be continued) 
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(b) I j 
丨 (25) 
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:^ ^^ ^ :^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ ^^ IPi^ ^^ ^^ ^^ ^^ ^^ ^^ H^liBHBBII^ ^^ W^^ ^^ ^^ ^^ ^^ ^^ HI^  
G/G,G/A,A/A 
j BsmAl polymorphism - A r g 4 5 0 - A G G / A 
j 
(c) (61) 
Exon 10, LDL receptor gene 
ArR450-AGG/A. Ahi^26l potymorphism 
pBR322 G/G A/A G/A G/A mm 
B m n i m ^ ^ i i 4 b p 
H ^ ^ ^ ^ B ; ; ^ i 0 8 b p 
^ ^ ^ ^ ^ ^ ^ ^ 1 




Exon 11’ LDL receptor gene, sequencing, Prosis-CCOT. Acil polymorphism 
L182(OT) L213(OT) 
A C G T A C G T 
• . . , u p ^ p ^ ' - m m - : 3 
® i f c ^ ^ " ^ ® ^ . . G ‘ 
"^ "^ B^BP®^� ^ ^ ^ ~«8Hr CAT 
t jjjm^ mm |mk c 
^ ^ H j L m 1 � 
^ ^ K ^ r ^ m K ^ ^ \ 八 Thrsn 
^ ^ ^ B | ^ ^ J ^ ^ ^ | M | ^ 
! ^ • ^ ^ H n i i H I H i 
i i I 
1 
Fig. 4-18 Identification of the 1617C/T Acil polymorphism from the PCR 
product of exon 11. (a) Confirmation by sequencing, (b) SSCP 
analysis, (c) Acil digestion analysis. The rare allele DNA retained the 
original size ofthe PCR product of 168 bp, while the wildtype DNA 
was cut into fragments of 113 and 55 bp. 
(to be continued) 
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(b) (32) 
Exon 11, LDL receptor gene, SSCP, 6%(49:1), 10%glycerol, RT 
err c/c 
丄 ； 
single -.…^ •_ - - ,. 
^ . *^ *WM<*HMfciaW*l>*fr. M^p* « . 睡 II 
strands mtlmmigllm 
flHMMnMM^^^^^M^^aB>*^>^ ^^^^^^^^^^^^^^^^®**®*i®miHBI^ ^BhtfHMMIfci • . "^ ^^^^^^MMii^ *Piimii^ ^^^^^^^p ^^^^^^KKKKftW 
'MHt^ "^ l^i#' ¾^^^ ,广_^  :iH|l|i|imifci 
double 
strands MMlkM^>MiMnBHMMflMbiBiHMiHNttli 4BMMlBll 
1 — 
(c) (65) 
Exon 11, LDL receptor gene 
Pro5i8-CCC/l, Acil polymorphism 
C / C T / T O T 
^ ^ H H H ^ I ^ 
a M 
H ^ ^ H | ^ n 168 bp 
^ ^ m Q | H 113bp 
^ ^ ^ m | ^ ^ 5 5 b p 
Fig. 4-10 (continued) 
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(a) I (42) 
j Exon 12, LDL receptor gene, sequencing, Asn570-AAOT, HmcW polymorphism 
； L12(CAT) L16(C/C) L39(C/C) L75(TAT) 
A C G T A C G T A C G T A C G T 
丨纖 
OT — p u p p ^ p j i ^ - f M j | ^ J L 
: - ' / & 5 ^ f e 
v ‘ 0 / P C " " ^ J 5 > ^ t f ^ | ^ 
丨 5’ i ^ • ^ ^ 0 : 
Fig. 4-19 Identification of the 1773C/T HincW polymorphism from the PCR 
product of exon 12. SSCP analysis is shown in Fig. 4-5b. (a) 
Confirmation by sequencing, (b) Acil digestion analysis. The rare allele 
DNA produced fragments of 157 and 52 bp, while the wildtype DNA 
produced fragments of 121, 52 and 36 bp. 




Exon 12, LDL receptor gene 
Astt57o-AAC/T, HincR polymorphism 
1 2 3 4 
I ~ 157bp 
^ 121 bp 
52bp 
i . 
Lanes: 1- lkb marker 
2 -C/C 
3 -C/T 
4 - T / T 
Fig. 4-15 (continued) 
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(a) (44) 
Exon 13, LDL receptor gene, sequencing, VaWGTlZQ，AvaU potymorphism 
L12(C/T) L16(TYT) L75(C/C) 
A C G T A C G T A C G T 
醒 .‘ —._ — •，• • 飄 — 
^ " 9 - m ^ m “ ^ ‘ iiJF^ 
^ ^ i j B ^ ' ^ , : ^ I ^ V m|^Bk 
flE 2 ¾ ! ^ ^ i i j 0 
c . ^ ¾ ! • 鎮 ^ _ 
T ^ \ W _ | V . . # • 
\ . w . ' H P _ g ^ ^ ^ ^ ^ Leu633 C ^ l ^ ^ ^ ^^ V P j ^ | i | 
T/C—— ^ ^ 夢 鍾 ^ S 
T m ^ ^ ^ m m - _ 
Va^ 32 G ^ ^ ' 2 p * * * '^** J | H r ^ 
T Z 一 j m _ . ^ t t ^ 看 ^ f ^ 
Met63i A / • 冒 , — . , . .〜 Wr ^"gm 
^^^^, aBBw^ '^^'*^***'**^^^  ^^ Hm^  j g j j ^ ^ 
^^mBF .. •-
5, 
Fig. 4-20 Identification of the 1959T/C AvaW polymorphism from the PCR 
product of exon 13. SSCP analysis is shown in Fig. 4-6b. (a) 
Confirmation by sequencing, (b) AvaW digestion analysis. The rare 
allele DNA produced fragments of 137 and 80 bp, while the wildtype 
DNA retained the original size of the PCR product of217 bp. 




Exon 13, LDL receptor gene, VaWGTT/C AvaU potymorphism 
i 
i ikb c/c Trr crr 
^ n m m n i i i j i i 2 i ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ j i ^ ^ i 
^ ^ n m n i i i i i 
B i ^ H l B B i ^ B I ： — — 2 i 7 b p 
n m ^ m i ^ m m i ^ m ^ ^ ^ m b p 
^ ^ • H . . 








Exon 15, LDL receptor gene, sequencing, Arg77 -^CGG/A. Mspl polymorphism 
L16 Normal 
A C G T A C G T 
5’ 9 P X 藥 
T ‘ " \ * ^ 1 
Arg723 C m k ^ B | | | k 
G^ — ^ m > ^ p p 
Pr0724 c W m ^ t g ^ ^ ^ f e m K ^ 
c ^ 'WKm ^ ^ ^ 
3 ^^ W^(BP|j(^  0fKi^- ^^^^^^^^ 
g m i i _ _ _ I ^ B 
^^«Mi '^ , __.. 'WKK: 
Fig. 4-21 Identification of the 2232G/A Mspl polymorphism from the PCR 
product of exon 15. (a) Confirmation by sequencing of DNA sample 
from L16 who is heterozygous for this polymorphism, (b) SSCP 
analysis of DNA samples from L16 and L79, two heterozygotes. (c) 
Mspl digestion analysis. The rare allele DNA produeced fragments of 
141 and 105 bp, while the wildtype DNA produced fragments of 120, 
105 and 21 bp. The 21 bp band was not seen on the gel. 




Exon 15’ LDL receptor gene, SSCP, 6%(49:1), 10% glycerol, RT 
L16 L79 
^ 華 爹‘雄丨•, 
霧 敏 、i_ii . 
single 
strands 
'swA' 0tl0 i0^ '^M'4|PfeMI 
double 
strands • • » *w^ 




E x o n 15, L D L recq>tor g e n e 
Ar^ 723-CGG/A. Mspl pofymorphism 
lkb G/G G/A 
H ^ H | P I ^ S ^ 2 4 6 bp (undigested) 
K £ L | | ^ m 一 141 bp 
m i i i i i i l ^ i30bp 
m m m � i o 5 b p 
Fig. 4-27 (continued) 
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(47) 
LDL receptor gene, Southern blot, BgHl, 5'-probe. 
L7 L12 L16 L22 L45 L69 L119 L148 L171 
-iK_i^ i^ i 
.. ,..- 鮮 - ,:- 13 Kb 
^^j | j^Hjj^  .“.=这.,.—'.4MI. i^^ ^ ^ 
'VPr W^ .… -"*^ . --^' ^ * ^ P | 9 . 5 Kb 
• . . . : : : ” : : � 
I 头'• •-i • • • 
I 
Fig. 4-22 Southern blot analysis with BgUl digestion and 5'probe hybridization. 
Genomic DNA samples from patients, L7, L12, L16, L22, L45, L69, 
L119, L148 and L171, were digested with BgRl and hybridized with 




LDL receptor gene, Southem blot, EcoRl, 5'-probe. 
L7 L12 L16 L22 L45 L69 L119 L148 L171 
II ||l|! 
I ™ 零 ‘ -
1 _ - ‘ 
I 31 
I 
！ _. _ _ _ _ _ - - -
Fig. 4-23 Southem blot analysis with EcoRl digestion and 5'probe hybridization. 
Genomic DNA samples from patients, L7, L12, L16, L22, L45, L69, 
L119, L148 and L171, were digested with EcoRl and hybridized with 




LDL receptor gene, Southem blot, Stul, 3'-probe. 
I 
U U 2 U 6 ^ ^ ^ M ^ ^ ^ ^ ^ 4 ^ 7 ^ C 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ | ^ ^ ^ ^ H ^ ^ ^ H 15Kb 
m ^ ^ ^ ^ l ^ l l ^ ^ ^ B ^ ^ P W i ^ i 7.2 Kb 
! ‘ T，1� 
‘ •••  •......械”^… .... I . .‘ ,•. i . , , . 
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Fig. 4-24 Southem blot analysis with Stul digestion and 3'probe hybridization. 
Genomic DNA samples from patients, L7, L12, L16, L22, L45, L69, 
L119, L148 and L171, were digested with Stul and hybridized with the 




LDL receptor gene, Southem blot, XbaR, 3'-probe. 
L7 L12 L16 L22 L45 L69 L119 L148 L171 C 
* ‘ ^ , ,, 
^ ^ ^ M 
,. ： • 書 • j ^ ^ ^ n m i _ 
' '5 : ^ ^ 9 B ^ | 
; " ‘ . “ � * ^ ^ P | | 6 -
^ y - ‘ . 、 二潘 
Fig. 4-25 Southem blot analysis with MaH digestion and 3'probe hybridization. 
Genomic DNA samples from patients, L7, L12, L16, L22, L45, L69, 
L119, L148 and L171, were digested with XbM and hybridized with 




Exon 18, LDL receptor gene 
Nco\ potymorphism 
lkb 
^ ^ ^ ^ ^ ¾ , ; ; ' ' )^RS.r I 一 9i6bp 
^ ^ ^ g | L . | — — 4 8 6 + 430 bp 
H i ^ ^ W 
Fig. 4-26 Restriction analysis for Ncol polymorphism in exon 18. The N- allele 
• 
retained the original size ofthe PCR product of 916 bp, while the N+ 




Exon 18, LDL receptor gene, TA repeats by PAGE 
U 3 b p ^ A ^ ^ i J | - e I % 
i “ 气 一 ^ ^ ^ I ， 4 
i � — H ^ ' ‘ l w J 
8 — ^ ^ ^ ^ ^ m i 
1—^^HB^^^^^W^^^^WHB 
• 1 




Fig. 4-27 Results for TA repeats polymorphism in exon 18. (a) PCR was 
performed with addition of a^^P-dCTP for labelling. Labelled PCR 
products were analyzed by 8% polyacrylamide gel electrophoresis, (b) 
Confirmation by sequencing to confirm the repeat numbers in two 
DNA samples. 
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Exon 4a, LDL receptor gene, sequencing, Ileioi-ATC^TTC-Phe 
Normal L70 
3' A C G T A C G T 
G\ • 
Argio3 C \ j r . 麵 « " ^ " " * ^ 3 
s 1 \9^1mjm 
serio2 T r ,mM^^^>^. ',,^^gmm^Sm 
c j j i ^ m ^ ^ ^ ^ j ^ ^ m ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ K 
X ^ ^ ^ ¾ ^ ' " ' f l | ^ 0 M I | ^ ^ H H ^ ^ H 
_ � 1 m — i m ^ m | ^ ^ ^ m 
1 ^ ^ ^ § £ ^ i | | j P 
Cysioo T |jB| u m i ^ ^ P ^ G / _ 哪 gm^ 
A / flBii i H » < ’ 





Fig. 4-1 Identification of the mutation 1101F from the PCR product of 5, half of 
exon 4 in patient L70. (a) Confirmation by sequencing, (b) SSCP 
analysis, (c) SfaNl digestion analysis for patient L70 and her three 
children, L300, L301 and L302. The mutant DNA retained the original 
size of the PCR product of 355 bp, while the wildtype DNA was cut 
into fragments of 225 and 130 bp. U: undigested PCR product; N: 
digested PCR product from a normal subject. 
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L70: Deioi-ATC^rrC-Phe 
(c) 
( 5 6 ) 
： E x o n 4 a , L D L r e c e p t o r g e n e 
i Ileioi-ATC^ITC-Phe, SfaNl d i g e s t i o n 
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Exon 7，LDL receptor gene, sequencing, Cys308-TGC^TAC-Tyr 
Normal L33 L139 
A C G T A C G T A C G T 
•3’ ‘ •— «•«<»-
3 二―. 〜一 . ***^ ^iiHi 
m _ 藝 
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Fig. 4-2 Identification ofthe mutation C308Y from the PCR product of exon 7 
in patients L33 and L139. (a) Confirmation by sequencing, (b) SSCP 
analysis . (c) BrsDl digestion analysis for patient L33 and family 
members. The mutant DNA retained the original size of the PCR 
product of 169 bp, while the wildtype DNA was cut into fragments of 
91 and 78 bp. 




Exon 7，LDL receptor gene, SSCP, 6% (49:1), 10% glycerol, RT 
L33L139 
� . � < N 4 P …嚇 
single 
strands 
.4MMMMig4p « 4 1 1 ^ � 
！ 
double 
^ m ^ 4flH .^ ^m^ strands 
L33,L139: Cys308-T^ T^AC-Tyr 
i 
(C) ！ (53) 
Exon 7, LDL receptor gene, Cys308-TGC^TAC-Tyr, BrsDl digestion 
I 
I L33 L116 L117 L122 L123 L124 mgm 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ g - 169 bp 
^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H - 9 1 b p 
^ ^ ^ ^ ^ ^ • l l ^ ^ ^ ^ ^ ^ ^ l - bp 
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Fig. 4-27 (continued) 
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j Exon 9’ LDL receptor gene, sequencing, Leu393 -CTC^CGG-Arg 
I L61 L66 
A C G T A C G T 
I 3 ' 
I . i -
！ 'mmf^^ ‘ — � 
幽 / A 'lflHHK itfMHte Z 
Wm W / G Asp394 
G 
T/G 
4MMi^  <4MHM^  C Leu/Arg393 
;••.'，:"•.- . ' ’ :��� ,� G 
.-^mg*Wfe- '^^S*"W^w^v.-� C 
\ A Thr392 
^»mmf£i^.. 4igiMaiiir X 
* ^ \ G 
\ T 
.>'4^ ^似 1 
—m^ "� 
麵 . ^ 3' 
Fig. 4-3 Identification of the mutation L393R from the PCR product of exon 9 
in patients L61 and L66. (a) Confirmation by sequencing, (b) SSCP 
analysis showing L393R for patients L61 and L66, V408M for patients 
L28 and L86, 1216C/A Mspl polymorphism for patient L148, and a 
different SSCP pattem for patient L171 in which the base change was 
not identified by sequencing, (c) BsmFl digestion analysis for patients 
L61, L66 and L261. L175 is a family member with FH phenotype of 
L61. The mutant DNA produced a fragment of 118 bp, while the 
wildtype DNA was cut into fragments of 87 and 31 bp. The second and 
third lanes from the left were digested PCR products from normal 
subjects. 




Exon 9，LDL receptor gene, SSCP, 6%(49:1), 10% glycerol, RT 
L28 L61L66 L86 L148L171 
1 _: • • - • f 
single 




！ strands i — ……. , 
,.-:¾ -
I L28, L86: VaLu)8-GTG^ATG-Met 
I L61, L66: Leu393-CIG^CGG-Arg 
I L148: Arg385-C/AGG, Mspl polymophism 
I L171: unknown 
(C) 
(52) 
Exon 9, LDL receptor gene, Leu3q3-CTG^CGG-Arg, Bsmf[ digestion 
L61 L175 L66 L261 
• 
^ ^ ^ ^ ^ ^ ^ ^ H I H H ^ ^ ^ H H — i84bp ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 9 
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Fig. 4-27 (continued) 
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(a) (29) 
Exon 10, LDL receptor gene, sequencing, Asp471-GAC^ MC-Asn 
L176 L66 
A C G T A C G T 
0 ’ 4il^Pii^  
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|j^BMii ^ 5 f e s 
Fig. 4-4 Identification of the mutation D47 lN from the PCR product of exon 10 
in patient L176. (a) Confirmation by sequencing. L66 is a normal 
control for this mutation, (b) SSCP analysis . (c) Plel digestion 
analysis for patient L176 and family members. L204 is the spouse, 
L203 and L205 the children of L176. The mutant DNA retained the 
original size of the PCR product of 298 bp, while the wildtype DNA 
was cut into fragments of 156 and 142 bp. The other lanes were 
digested PCR products from normal subjects. 




Exon 10，LDL receptor gene, SSCP, 6%(49:1)，10% gfycero^ RT 
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Fig. 4-4 (continued) 
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Exon 12, LDL receptor gene, sequenc>ng, 1779delC at G l y 5 7 2 GGC 
L39 Normal 
！ A C G T A C G T 
會飞 I^ H^^v N^MM^ _^^^B|k 
>-,its0/. •»：••  i|^ ^^ ^^ ^^ ^^ ^^ ^^  ^^^tK^r 
3’ 1 ^ m : 
\\、mM t/F . 
Asns73 A m ^ ^ ^ r f H ^ ^ L _ 
C/del— ^ ^ ^ ^ H H ^ ^ ^ ^ | j j k 
G Majj|m^^mg^^^^tf^^^^^^^^^^^^^^^^^ 
Giy572 / g ^ ^ ^ m n i i i i ^ ^ m 
Giy571 ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ® 
5， 
i 
Fig. 4.5 Identification ofthe mutation 1779delC from the PCR product of exon 
12 in patient L39. (a) Confirmation by sequencing, (b) SSCP analysis 
showing 1779delC and 1773C/T EincW polymorphism, (c) Nla\N 
digestion analysis for patient L39. The mutant DNA produced 
fragments of 110 and 99 bp, while the wildtype DNA retained the 
original size of the PCR product of 209 bp. The other lanes were 
digested PCR products from normal subjects. 




Exon 12，LDL receptor gene, SSCP, 6%(49:1), 10% glycerol, RT 
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L39: 1779delC at codon 572 
C7T: Asn570-AACa;, HincU polymorphism 
(c) I ( 5 8 ) 
Exon 12, L D L receptor gene, 
I 1779delC at Gly572 GGC, NlalW digestion 
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1 Exon 13’ LDL receptor gene, sequencing, 
！ L75: Ala606-GCC^ACC-Thr, L79: Ala,o6-GCC^GIC-Val 
L79 L75 Normd 
A C G T A C G T A C G T 
3’ ^ g _ 漏 _ 漏 書 
Cv ^^^ • 丽 n n " 
T \ ^ ^ ^ ^ ^ ^ 麵 . ^ ^ H J 
T \ '^K^^ |^Mg^^^^^ ^^ ^^  iBMi^ flH^ ^ ^^ ^^  i^jimi^ ^^ ^^  
T \ ^ ^ < I P ^ ^ ^ B i ^ l f ^ ^ m g m ^ K ^ 9 
J �^^ «* ^^^^ •• ^^^W^*WP^ ^^ 
Ue607 A | B i B ^ | H 
C • • • • • ^ ^ ^ 聊 
AWVaU cn一 ^^^*HBP . ^^冊 ^^^_ 
Ala/ThT606 G/A^ 響 _ 一 .翁攀 ^ J _ 售 
A / i ^ ^ . _ • — — 2 ^ — 
Glu605 G/ • • ^ ^ ^ 擊 | j j ^ J _ j p 
5, K 一- "^^ *^ "^ Bf 一 ^^^^® 
Fig. 4-6 Identification of the mutation A606T and A606V from the PCR 
product ofexon 13 in patients L75 and L79 respectively. No restriction 
analysis result for these two mutations, (a) Confirmation by 
sequencing, (b) SSCP analysis showing A606T, A606V and 1959T/C 
Avall polymorphism, (c) SSCP analysis for family members of L79 
with the A606V. L135 is the mother ofL79 from whom the mutation is 
inherited. L131 is the father and L133 the uncle both are normal. L129 
is the brother who also carries the mutation. The other lanes were PCR 
products from normal subjects. 
(to be continued) 
119 
Chapter 5: Discussions 
5.1 Use of SSCP in Screening for Mutations and 
Polymorphisms 
SSCP is an useful and popular method for screening for mutations and 
polymorphisms, it is simple and requires no special equipment. However, the 
efficiency and sensitivity could vary and false negative results are common (Hayashi, 
1992). Experimentally one should try as many SSCP electrophoresis conditions as 
possible to minimize the occurrence of false negative and increase the efficiency. 
Therefore we performed our SSCP analyses under 4 electrophoresis conditions: 
combinations of including and excluding 10% glycerol and electrophoresis at room 
temperature or at 4^C. These are the two more important factors influencing single 
strand conformations (Hayashi, 1991). 
i 
:j 
Our SSCP analysis showed glycerol to be crucial to differentiate SSCP patterns of 
1 PCR products having base changes, no differentiated SSCP patterns could be obtained 
without glycerol in the gel (Table 4-2). Glycerol by its weak denaturing action opens 
the folded structure of single strand DNA and results in formation of different 
structural conformations due to small or single sequence changes. Our results 
confirmed that glycerol is essential for the formation of different conformations of 
single strand DNA with small sequence differences (Hayashi, 1991). 
158 
According to our results, the electrophoresis temperature is another important factor 
determining single strand conformation. Firstly it has to be stable. Secondly different 
temperatures produced different SSCP patterns. Electrophoresis at room temperature 
accounted for 9 out of 13 SSCP results (Table 4-2). Room temperature is somewhat 
arbitrarily defined as around 22^C. This temperature is thought to be close to the 
melting temperature of small regions of base-pairing of the single strands which are 
responsible for the conformation (Humphries et al, 1996). However, in 4 ofour SSCP 
analyses, electrophoresis at 4^C but not at room temperature gave differentiated SSCP 
patterns (Table 4-2). It also showed that the conformation of single strand DNA can 
be changed dramatically by gel temperature during electrophoresis (Hayashi, 1991). 
There are other electrophoresis parameters such as the acrylamide percentage, degree 
of crosslinking, double strand denaturation and buffer composition that may affect the 
efficiency of SSCP. Different SSCP patterns might be detected by varying these 
parameters. From our SSCP analysis, all the 6 common polymorphisms that had been 
reported in the coding regions of exons ofLDL receptor gene were detected (Table 4-
4) (Yamakawa-Kobayashi, 1993; Saint-Jore et al. 1993). We also detected one novel 
j 
I 
polymorphism and one rare silent mutation in addition to the 13 mutations. It is 
unlikely that any base change was missed out by our technical approach (Humphries 
et al, 1996). No further SSCP analysis was carried out for the LDL receptor gene of 
the 9 FH patients in whom the mutations responsible for FH are still unknown. 
159 
5.2 Novel and Reported Mutations 
The 13 mutations identified in the FH patients in this study scattered over the LDL 
receptor gene, and they changed conserved amino acid sequences in different 
functional domains ofthe mature protein. These 13 mutations are depicted in Fig. 5-1. 
All five classes of LDL receptor mutations were present (Table 4-3). The I101F and 
E207K are mutations in the ligand binding domain, C308Y and C656F in the EGF 
precursor homology domain affecting the disulfide linkage formation, L393R, 
V408M, D471N, 1779delC, A606T, A606V and P664L in the spacer region of the 
EGF precursor homology domain affecting the structural conformation, and finally, 
V776M in the membrane spanning domain causing a splice error. When family 
members were available for study, the mutations were shown to be co-segregating 
with and therefore responsible for the FH. 
The properties and effects of each of the novel and recurrent mutations found in this 
study are discussed in detail below (Fig. 5-1). 
5.2.1 The -44C—T promoter mutation occurred in the repeat 3 of the three direct 
repeats of a 16 base pair sequence which is homologous to the consensus DNA 
sequence and is recognized by the positive transcription factor Spl (Dawson et al, 
1988). The repeat 3 binds strongly to purified transcription factor Spl and is a 
constitutive positive transcriptional element that acts independently of sterols. 









































































































































































































































































































































































































































































































































































sequence in which sterol-regulated binding with a nuclear protein could suppress the 
activity of the Spl binding in repeat 3 and thus the gene transcription (Dawson et al, 
1988). Single base substitutions of the repeats 2 and 3, especially in the central 
nucleotides: -56 to -63 in repeat 2 and -40 to-47 in repeat 3, are able to abolish the 
expression. There is another direct repeat of the 16 bp sequence, repeat 1, upstream at 
-88 to -103, which is also a Spl binding site. Together with a TATA-like sequence at 
15 nucleotides downstream from repeat 3，these elements form the promoter for the 
LDL receptor gene which is negatively regulated by sterols (Sudhofet al, 1987). Four 
other mutations in the promoter region have been discovered: two are single base 
substitutions in repeat 3 at -42C—T (Hobbs et al, 1992), -43C—T (Koivisto et al, 
1994) and -45C~>T (Sun et al, 1995), and one is a three bp deletion in repeat 1 (van 
Wingerden, 1981). Mutations at the promoter have been shown to reduce 
transcriptional activity and leading to low levels of mRNA (Koivisto et al, 1994; Sun 
et al, 1996). The LDL receptor gene promoter is relatively small, less than 200 bp in 
size, and except for repeat 3 which seems to be a hotspot for mutations, only 1 small 
deletion has been described. Therefore, mutations of the promoter in the LDL receptor 
gene are relatively uncommon as compared with the large number of mutations 
1 occurring in other regions of this gene. In one study, no promoter mutation was found 
in 350 Dutch FH patients screened for mutations by denaturing gradient gel 
electrophoresis (Top et al, 1992). However, the fact that one in 24 of our Chinese FH 
patients have a promoter mutation does not indicate promoter mutations to be 
common in Chinese. 
j 
I 
] — i 
I • 
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Investigations by PCR-SSCP analysis, direct dsDNA sequencing and Pstl enzyme 
digestion of family members of patient L25, who had the -44C^T mutation, found 
another mutation, P664L, in exon 14 (Fig. 4-12a and b). A younger brother of L25 
carried both the -44C—T and P664L mutations and he is a compound heterozygous 
FH subject (Fig. 4-8c). The P664L mutation was inherited from the patient's father, 
but the patient's mother did not carry either mutation. The compound heterozygous 
FH patient had coronary artery bypass graft done at his age of 27, his plasma 
cholesterol level was around 12 mmol/L despite treatments including plasmapheresis. 
5.2.2 I101F was a novel mutation found in our study. This isoleucine residue 101 is 
located next to a cysteine residue at position 100 which is situated 8 residues upstream 
to the repeat 3 in the ligand binding domain and required for the formation of a 
disulfide linkage. This cysteine-isoleucine pair is also preserved in other repeats at 
positions 18/19, 61/62, 139/140, 188/189, 227/228 and 268/269. Substitution of this 
isoleucine by phenylalanine might disrupt the disulfide bond formation and produce a 
Class 3 mutation by decreasing the ligand binding activity (Hobbs et al, 1992). The 
mutation co-segregated with FH phenotype among the family members of patient 
L70. This I101F was the first mutation found with the isoleucine of these cysteine-
isoleucine pairs. 
5 2.3 The mutation E207K was first described in French Canadians with a frequency 
of 2% of the FH mutations and is one of the common mutations in this ethnic group 
(Leitersdorf et al, 1990). The mutation occurs at a CpG hotspot in which the G has 
been reported to be mutable to either A, C or T (Hobbs et al, 1992). The G—T 
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mutation at this nucleotide creating a stop codon has been reported in a Chinese FH 
patient (Sun et al, 1994), and other nucleotide changes in different ethnic groups 
suggesting that they have occurred probably independently during evolution. 
Glutamic acid 207 is at the conversed sequence, Asp-x-Ser-Asp-Glu, at the 3'-end of 
repeat 5 in the ligand binding domain. Its negative charge is responsible for binding to 
the ligand apolipoprotein B (Sudhofet al, 1987). It is highly conserved in all repeats 
and substitution of this amino acid would no doubt affect the function of the LDL 
receptor protein. 
5.2.4 C308Y was a novel mutation found in our study. For the C308Y mutation, the 
cysteine residue 308 is situated in repeat A which is the first cysteine rich region of 
the epidermal growth factor (EGF) precursor homology domain (Sudhofet al, 1985). 
It is highly conserved throughout the repeats of the domain, not just in the LDL 
receptor, but also in the homologous regions of the EGF precursor, factor IX, factor X 
and protein C ofdifferent species (Yamamoto et al, 1984). Cysteine 308 is important 
for the correct folding of the LDL receptor protein, hence for its function, and 
therefore mutation C308Y may produce an unstable protein leading to a Class 2B 
transport defect mutation, similar to the nearby C297Y (Hobbs et al, 1992) and C317S 
(Maruyama et al, 1995) mutations. This mutation co-segregated with the FH 
phenotype in families ofboth FH patients. 
5 2.5 L393R was a novel mutation found in our study. For the L393R mutation, the 
leucine residue 393 is situated in the first ofthe five repeats of 40-60 amino acids in 




regions, A and B, from the third, C, and are highly conserved. These repeats and the 
whole EGF precursor homology domain have a compact structure which is easily 
disrupted by even a single amino acid change (Goldstein et al, 1995). L393R may be a 
Class 5 recycling defect mutation similar to the nearby E387K and V408M (Hobbs et 
al, 1992). Both L61 and L66 have the same haplotype for the mutation and therefore it 
is possible the mutation was inherited from a common ancestor. 
5.2.6 Mutation V408M was first described in the Afrikaner population in South 
African leading to a Class 5 mutation as L393R (van de Westhyzen et al, 1984) and 
occurs at a frequency of 30% ofthe FH mutations due to a founder effect. Later, the 
same mutation was identified in the Dutch and German (Schuster et al, 1993) 
populations from which South African Afrikaners originated. They descended from 
several families that emigrated to South Africa in the 17th and 18th centuries. It 
should be noted that this mutation occurs at lower frequencies in Holland and in 
Germany. In addition, the South African Afrikaners, Dutch and Germans all have the 
same haplotype for the LDL receptor gene (Schuster et al, 1993), and these common 
genotypic features are highly supportive of the assumption of an European origin of 
the mutation. Of the 7 polymorphisms that defined the haplotype for V408M 
(Schuster et al, 1993), we have determined Hincll+, AvaW- and Ncol- unambiguously 
in one subject, L86 (Table 4-5), which are the same as in the original German 
haplotype. It would be usefiil if our and their patients were haplotyped with the same 
set of polymorphisms to confirm whether the V408M in Chinese was occurred 
independently or not. However, due to the geographical distance and historic ethnic 
difference, it is highly probable that this mutation has arisen independently in 
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Chinese, especially this occurs at a CpG dinucleotide sequence which is known to be 
a hotspot for mutation in the human genome (Cooper and Krawczak, 1990). 
5.2.7 D471N was a novel mutation found in our study. For the D471N mutation, the 
aspartic acid residue 471 is in the EGF precursor homology domain which contains 5 
repeats of 40-60 amino acids. In each of the 5 repeats, there is a highly conserved 
motif, Tyr-Trp-Thr-Asp (YWTD), and the aspartic acid residue 471 belongs to this 
motif in repeat 2. The repeat is part of the LDL receptor protein involved in the 
recycling process (Hobbs et al, 1992). Therefore, mutation D471N would produce an 
unstable protein precursor or a protein defective in the recycling process leading to a 
Class 2B transport or Class 5 recycling defect mutation. This is analogous to the 
D558N mutation affecting a similar functional domain (Hobbs et al, 1992). 
5.2.8 We found one novel single base pair (bp) deletion occurring in exon 12 codon 
572. It resulted in a truncated protein with a stop codon by frameshift 72 codons 
downstream to the deletion site and leading to a Class 1 null allele mutation. 
Unfortunately, no family member of this patients was available for study. This was 
the only single bp deletion found in our study, although single bp deletions had been 
reported at codons 650, 651 and 850 in Chinese FH patients (Sun et al, 1994). They 
are all situated at the 3, half of the LDL receptor gene. However, it is likely that small 
deletions would be found in the 5'-half of the LDL receptor gene when a larger 
number of Chinese FH patients are available for study. 
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5.2.9 Two mutations in exon 13 were identified in two patients, they are at codon 
606: A606T and A606V. The latter was a novel mutation found in our study. The 
alanine residue 606 is adjacent to the conserved motif, Tyr-Trp-Thr-Asp (YWTD) in 
repeat 5 of the EGF precursor homology domain, encoded by codons 598 to 601 of 
exon 13 (Yamamoto et al，1984). Mutations A606T and A606V affect the recycling 
process of the LDL receptor protein after binding with ligand and uptake into the cell 
leading to a Class 5 defect (Sun et al, 1994). These 2 mutations are the only mutations 
known to exist in exon 13 in Chinese but not other populations. In contrast, in exons 9 
to 12 which code for equivalent functional parts as does exon 13, i.e. the first 4 
repeats in the EGF precursor homology domain, mutations are frequently detected in 
both the Oriental and Caucasian populations (Hobbs et al, 1992). The A606T has been 
reported previously in a Chinese FH patient from Nanjing in Jiang Zu in China (Sun 
et al, 1994). Our 2 patients, one with the same A606T and one A606V, are from Hong 
Kong and originated from Guang Dong. These are regions in China south of the 
Yangtze River. Therefore, it is possible that mutations in exon 13 ofthe LDL receptor 
gene are unique to Chinese in southem China. Overseas Chinese in East Asia and 
Europe are mostly derived from southem Chinese while Chinese in North America are 
more heterogeneous in their origins. Therefore mutations in exon 13 of the LDL 
receptor gene should be investigated specifically in Chinese populations around the 
world to look for founder effects. 
5 2.10 In exon 14, there were 2 mutations, C656F and P664L, and the former was a 
novel mutation found in our study. For the C656F mutation, the cysteine residue 656 
is in repeat C ofthe EGF precursor homology domain. Cysteine 656 is one ofthe six 
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cysteine residues in repeat C and mutation of this cysteine could disrupt the formation 
ofthe disulfide linkage and preventing the correct folding of the protein (Sudhofet al, 
1987). A different mutation has been reported in this codon. It is a T~>C at nucleotide 
2229 that changed cysteine (IGC) to arginine (CGC) in an American FH patient 
producing a Class 2A mutation (Hobbs et al, 1992). A mutation C646F nearby has 
been also reported which leads to a Class 2A mutation (Leitersdorf et al, 1990). 
5.2.11 In exon 14, the P664L is a previously reported mutation of C—T at nucleotide 
2054 that changed codon 664 for proline to leucine in patient L13. This mutation in 
the repeat C ofthe EGF precursor homology domain was firstly reported in an Indian 
(Soutar et al, 1989). The mutation affects the intracellular processing of the protein 
and produces a Class 2B transport defect mutation. Later this mutation was described 
in various ethnic groups including British, Norwegian and Dutch in Netherlands and 
Canada (King-Underwood et al, 1991). Furthermore, at least 2 haplotypes have been 
described, one for the British and one for the Dutch/Norwegian/Indian populations. 
Although the Dutch/Norwegian and Indian mutation have the same haplotype, the 
mutation is more likely to have occurred independently rather than from a common 
ancient mutation because of the great geographical distance between these 
populations. Therefore, this mutation would have been occurred 3 times during 
i 
I 
evolution (King-Underwood et al, 1991). The haplotype of our patient with mutation 
P664L, HincW+, Avall- and Ncol- (Table 4-4), is the same as the British but not the 
Indian haplotype. For the same reason of geographical distance, it is likely that the 
I 
mutation recurred independently. However, the haplotype associated with the British 
P564L is the most common haplotype in the UK and USA (King-Underwood et al, 
j 
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1991)，similarly, our haplotype for the Chinese P664L is also the most common type 
in our patients (Table 4-5), therefore, it is still possible that this is an ancient mutation 
common to both the British and Chinese. The frequency for P664L is from 0.8 to 
3.3% among FH patients in various populations including Japanese (King-Underwood 
et al, 1991; Defesche et al, 1992; Maruyama et al, 1995). It is therefore possible a 
common mutation worldwide and more Chinese FH patients should be screened for 
this mutation. Patient L13 carrying this P664L mutation is the brother of L25 who 
carries the promoter -44C~>T mutation. 
5.2.12 The V776M has recently been reported in Spanish descendants in Cuba 
(Pereira et al, 1995). In our study, this mutation co-segregated with FH in the family. 
The haplotype, SfaNl+, AvaW-, Ncol+ and TA=7 (Table 4-5) is the same as reported 
for the Cuban Spanish descendants (Pereira et al, 1995). However, due to the 
geographical distance and historic ethnic difference, it is again highly likely that this 
mutation has arisen independently in Chinese, especially this occurs at a CpG 
dinucleotide sequence which is known to be a hotspot for mutation in the human 
genome (Cooper and Krawczak, 1990). Valine residue 776 is within the membrane-
spanning domain and substitution with a methionine may cause a Class 4 
internalization defect mutation (Pereira et al, 1995). However, this nucleotide is also 
the last base of exon 16 of which G is the consensus sequence conserved at a 
frequency of about 80% for the mammalian 5, splice site (Horowitz and Krainer, 
1994). In one review study, this G mutation accounted for 6 out of 62 5'-splicing 
errors (Krawczak et al, 1992). It is possible that this mutation causes a 5’ donor site 
splicing error. RNA samples from the patient was investigated by reverse transcription 
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(RT) followed by PCR (Fig. 4-13d). The RT-PCR product was sequenced and only 
the normal G allele was found (Fig. 4-13e). Ifthe G~>A mutation caused a donor type 
splicing error, intron insertion or skipping would occur. Abnormal and unstable 
mRNA in a very small quantity would be produced when compared to normal mRNA 
(Krawczak et al, 1992). Its amplification by RT-PCR would not be easy. Nevertheless, 
the observation of only the normal G allele with the mRNA analysis did indicate a 
splicing error. This mutation of G—A at the -1 position of the 5’ donor splice site 
causing a splicing error has not previously been reported for the LDL receptor gene. 
5.3 Novel Polymorphism and Silent Mutation 
5.3.1 The 1216C/T Mspl polymorphism in exon 9 was a novel polymorphism found 
in our study. The C—A base change at nucleotide 1216, which does not alter the 
codon 385 for arginine was found in two of our FH patients. Although, the 
polymorphism did not co-segregate with the FH in both families (Fig. 4-14b) since the 
rare A allele was found in one family member not suffering from FH. The rare A 
allele was absent in 178 normocholesterolaemic subjects suggesting there might still 
be a possible association with FH (Table 4-4). The LDL receptor gene mutations of 
these two patients were not identified by our PCR-SSCP analysis. 
This polymorphism has not been reported in Caucasians (Saint-Jore et al, 1993) and 
Japanese (Yamakawa-Kobayashi et al, 1993) and is possibly unique in Chinese. This 
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C—A base change may have arisen independently after the Chinese separated into a 
different phylogenic branch during evolution of this gene, or it might be a relatively 
recent mutation of nucleotide 1216 which is located at a CpG hotspot. The FH 
patients in this study were all residents in Hong Kong who originated from southem 
China. It would be interesting to screen for this polymorphism in Chinese FH 
families, in different regions of China to study for regional segregation in the same 
ethnic group. If the frequency of this polymorphism could be obtained in Chinese 
from other parts of China and other populations around the world, it would be useful 
in elucidating the phylogenic relationships among Chinese and between different 
populations (Leitersdorf et al, 1989b). 
5.3.2 A novel silent mutation, S765S, was found in exon 16 in patient L45. No 
mutation was identified for this patient by our PCR-SSCP analysis. By MaR 
restriction enzyme analysis, 178 normocholesterolaemic subjects did not possess the 
mutation. Therefore, although this mutation did not change the serine residue at 
position 765, it might be in linkage with the unknown LDL receptor gene mutation 
responsible for FH in this patient. 
5.4 Common Polymorphisms 
Using our SSCP protocol, all 6 common polymorphisms reported in the exons ofthe 
LDL receptor gene were detected in our patients (Table 4-4). They were the SfaNl in 
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exon2, Alw26l in exon 10, Acil in exon 11，Hincll in exon 12，AvaW in exon 13 and 
Mspl in exon 15 (Yamakawa-Kobayashi, 1993; Saint-Jore et al, 1993). An exception 
is the Stul in exon 8, but the rare allele ofthis polymorphism has not been identified 
in Chinese (Humphries, personal communication). The Ncol in exon 18 is within the 
untranslated region which was not included in the PCR amplification in our study. For 
HincW in exon 12 and AvaW in exon 13, the frequencies found in our study were 
consistent with those reported in Japanese (Yamakawa-Kobayashi et al, 1993) with 
rare allele frequencies about 0.2. This is different from Caucasians in which the 2 
alleles are present at about equal frequencies (Humphries et al, 1993; Rodninger et al, 
1993; Zee et al, 1995). This suggests the Oriental populations would be on a separate 
phylogenic branch ofthe evolution of the LDL receptor gene. 
5.5 Possible Common Mutations of the LDL Receptor Gene in 
Chinese 
Among the 24 unrelated FH patients, there were 3 mutations, C308Y, L393R and 
V408M, that occurred twice in two patients and therefore accounted for 25% (6 out of 
24) of all patients. The families of these six patients were originated from the Guang 
Dong province in southem China. Since they possessed the same haplotype (Table 4-
5), they might be descendants of the same ancestor. It is possible that these three 
mutations, in particular the L393R, are the common mutations for Guang Dong and 
Hong Kong Chinese (Mak et al, 1996b). Since L393R and V408M are both in exon 9, 
! 
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screening ofexon 9 by PCR-SSCP could then detect mutations in at least 16.7% (4 in 
24) of our FH patients. This suggests a rapid method for genetic diagnosis of FH in 
Hong Kong. 
These three mutations, C308Y, L393R and V408M, occurred in our FH patients 
originated from southern China, were not detected in a previous study ofHan Chinese 
from central China (Sun et al, 1994). This strongly suggests regional segregation of 
mutations in the LDL receptor gene in China. This further supports the possibility of 
I 
some kind of "founder effect" for the Chinese in southern China who were emigrants 
and descendants from common Han ancestors around the Yangtze River area in 
Central China (Zhao and Lee, 1989; Sun et al, 1994). The situation is analogous to the 
V408M found in South African Afrikaners. To search for common or founder 
mutations in a large population of 1.2 billion Chinese is difficult. Our discovery of 
three possible common mutations and the rapid detection methods established in our 
study provide a practical direction and approach for investigation of clinically 
diagnosed FH patients in Chinese (Mak et al, 1996b). 
5 6 Pattern of LDL Receptor Gene Mutations in Chinese 
We have completed the screening for mutations in the LDL receptor gene in 24 
Chinese FH patients from Hong Kong. Thirteen mutations were identified of which 
seven were first described in our study. With the exception of one, the rest 12 
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mutations are different from the 12 mutations reported for Chinese in previous studies 
(Hobbs et al, 1992; Sun et al, 1994). We have shown three mutations, C308Y, L393R 
and V408M, to be the possible common mutations for Hong Kong Chinese (Mak et 
al, 1996b), whereas in the previous study in Chinese, no mutation was found in more 
than one unrelated individual (Sun et al, 1994). There might be regional differences 
since the previous 12 mutations were all found in FH patients from Nanjing in Jiang 
Zu, a province in central China, and our patients originated from Guang Dong, a 
province in southern China. 
Together with the previous report on Chinese, there are 24 LDL receptor gene 
mutations described in Chinese FH patients. Among these 24 mutations, 17 have not 
been reported in other populations. They scatter over the LDL receptor gene and are 
heterogeneous as in other populations as a whole for Chinese. Unlike the Japanese, 
there were common mutations reported (Mamyama et al., 1995), but we have 
identified possible common mutations (Mak et al, 1996b). 
These 13 mutations were found in the promoter and exons 4, 7，9, 10, 12, 13, 14 and 
16, and they changed the conserved amino acid sequences in different fiinctional 
domains ofthe mature protein leading to all five classes of mutations (Table 4-3). The 
I101F and E207K are mutations in the ligand binding domain, C308Y and C656F are 
in the epidermal growth factor (EGF) precursor homology domain affecting the 
disulfide linkage formation, L393R, V408M, D471N，1779delC, A606T, A606V and 
P664L are in the spacer region of the EGF precursor homology domain affecting the 
structural conformation, and finally V776M is in the membrane-spanning domain 
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producing a splice error. When family members were available for study, the 
mutations found co-segregated with the FH phenotype and were therefore probably 
responsible for the FH. 
Mutations associated with CpG hotspots may account for about one-third ofall single 
base pair substitutions that lead to genetic diseases (Cooper and Krawczak, 1990). 
Five out of the 13 mutations found in this study, which was close to one-third, 
involved CpG hotspot mutations: E207K, V408M, D471N, P664L and V776M. 
Meanwhile, only three of our patients carrying the V408M, P664L and V776M 
mutations have the same haplotypes (Table 4-5) as the original German {HincW+, 
Avall- and NcoV) (Schuster et al, 1993), British {HincW+, AvaW- and Ncol-) (King-
Underwood et al, 1991) and Spanish haplotypes {SfaNl^, AvaW-, Ncol+ and TA=7) 
(Pereira et al, 1995) respectively. Our findings support the hypothesis that these FH 
mutations in Chinese have been arisen independently during evolution. This 
hypothesis is supportedly the fact that the Chinese are historically separated from the 
Caucasian populations by long geographic distance and distinctive cultural heritage. 
From our Southem blotting results, no large deletions, insertions or rearrangements 
were found. One large deletion of exons 11 to 14 has been reported in a Chinese 
subject (Sun et al, 1994). Large deletions, insertions or rearrangements could account 
for about 15% ofall mutations of the LDL receptor gene in other populations (Hobbs 
et al, 1992). Study on larger number of Chinese FH patients is needed to look for 
these types ofmutations. Nevertheless, there were 5 small deletions (one in our study 
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and four in the two previous studies) out of 24 mutations, and this proportion is 
consistent with findings in other populations (Hobbs et al, 1992). 
In this study, 13 mutations from 24 heterozygous FH patients with 22 mutated alleles 
were detected, and the efficiency ofthe PCR-SSCP screening was 59%. In a previous 
study, 10 mutations were detected from 17 mutated alleles in 10 homozygous FH 
patients (Sun et al, 1994) giving also 59% of efficiency. Therefore, the capability of 
PCR-SSCP techniques to detect base changes is reassuring. For those FH patients in 
whom mutations could not be identified, a possible explanation is that the genetic 
defect is not within the regions that are screened by our PCR protocols, and may be 
lying in other undefined control elements. It is also possible that the genetic defect 
may not be in the LDL receptor gene, but in genes that code for proteins which are 
essential for LDL receptor function. This could be investigated by linkage studies to 
identify other possible gene loci, but the number of FH families in this study is too 
small to be informative. 
In summary, LDL receptor gene mutations in Chinese are heterogeneous and largely 
different from mutations reported in other populations. They scatter over the LDL 
receptor gene from the promoter to exons at the 3, end. The mutations include large 
and small deletions, nonsense and missense mutations and a splicing error mutation. 
No obvious founder mutation was observed, but our results in Hong Kong Chinese 
originating mainly from southern China indicated possible common mutations which 
may represent regional segregation of the LDL receptor gene mutations. To identify 
1 
i mutations or search for common mutations in a large population of 1.2 billion Chinese 
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is difficult. The 13 mutations identified in this study giving a total of 24 mutations 
reported in Chinese is far from completion to represent the whole Chinese population. 
More studies are needed to fully characterize the LDL receptor gene mutations in 
Chinese. We are in the process of screening mutations in the LDL receptor gene of 
further heterozygous FH patients in Hong Kong. When more genotypic data are 
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